Method for electrochemiluminescence detection
By using electrodes, binding partners and ECL-labeled oligonucleotide probes in ECL detection methods, combining non-TPA ECL co-reactants, the limitations and efficiency of molecular beacon probes are solved, and high efficiency is achieved. Low noise ECL signal determination.
Patent Information
- Application Number
- CN202280091791.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-30
- Filing Date
- 2022-12-22
- Publication Date
- 2024-11-08
Smart Images

Figure CN118922555A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 295,470, filed on December 30, 2021, which is hereby expressly incorporated herein by reference in its entirety.
[0003] Reference to a sequence listing, table or computer program listing
[0004] This application is submitted in electronic format along with a sequence listing. The sequence listing is provided as a file named MSD_002WO2_Sequence_Listing.xml, which was last saved on December 22, 2022 and is 8.61 kb in size. The information contained therein is incorporated herein by reference in its entirety. Background Art
[0005] Many commercially available instruments use electrochemiluminescence (ECL) for analytical measurements. Compounds that interact with ECL labels and produce ECL are called ECL co-reactants. Common co-reactants include tertiary amines (see, for example, US 5,846,485), oxalates, and for the production of Ru(Bpy)3 +2The ECL of the present invention can be used as a reporter signal in a diagnostic procedure (see, for example, US 5,238,808). For example, the ECL label can be covalently coupled to a detection reagent, and the participation of the detection reagent in the binding interaction can be monitored by measuring the ECL emitted from the ECL label. Alternatively, the ECL signal from the ECL active compound can indicate the chemical environment (see, for example, US 5,641,623, which describes an ECL assay for monitoring the formation or destruction of ECL co-reactants). ECL-based assays are further described in U.S. Patent Nos. 5,093,268; 5,147,806; 5,324,457; 5,591,581; 5,597,910; 5,641,623; 5,643,713; 5,679,519; 5,705,402; 5,846,485; 5,866,434; 5,786,141; 5,731,147; 6,066,448; 6,136,268; 5 ,776,672; 5,308,754; 5,240,863; 6,207,369; 5,589,136; and 6,919,173 and International Publication Nos. WO99 / 63347; WO00 / 03233; WO99 / 58962; WO99 / 32662; WO99 / 14599; WO98 / 12539; WO97 / 36931 and WO98 / 57154, each of which is incorporated herein by reference in its entirety.
[0006] Commercially available ECL instruments are widely used due to their sensitivity, dynamic range, precision, and tolerance to complex sample matrices. Several types of commercial instruments are available for performing ECL-based measurements (see, e.g., Debad, JD et al., 2004. Clinical and Biological Applications of ECL. Electrogenerated Chemiluminescence. Marcel Dekker, pp. 43-78). ECL instrumentation is further described in, for example, U.S. Pat. Nos. 5,935,779 and 5,993,740 (bead-based ECL assays); U.S. Pat. Nos. 6,140,045; 6,066,448; 6,090,545; 6,207,369 and International Publication No. WO 98 / 12539 (ECL assays using immobilized binding reagents); U.S. Pat. Nos. 6,977,722 and 7,842,246 (multiwell plates with integrated electrodes for ECL assays); and U.S. Publication Nos. 2012 / 0190589 and US 2012 / 0178091 (box-based ECL assays), each of which is incorporated herein by reference in its entirety.
[0007] The ECL co-reactant tripropylamine (TPA) is commonly used in ECL-based assays.
[0008] Molecular beacons are molecular probes that are oligonucleotides that contain a stem and a loop, a quenching moiety, and a fluorescent moiety that interact in such a way that, in the absence of a target sequence, the quenching moiety reduces the fluorescent signal from the fluorescent moiety when the fluorescent moiety is close to the latter. Under ideal conditions, this molecular probe is capable of producing a 200-fold increase in fluorescence upon hybridization. However, this type of molecular beacon is generally limited to a single analyte (or, in the above case, a target sequence) that can be measured at a given time. In addition, such molecular beacons with their fluorescent moieties are not easy to control and have a limited lifespan due to photobleaching. Additionally, these types of molecular beacons require multiple incubation and washing cycles that can extend the duration of the assay and therefore reduce efficiency. Examples of molecular beacon probes with ECL labels are disclosed in Chem. Commun. 21: 2710-2711 (2003) and Sensors & Actuators: B. Chemical 330: 129-261 (2021). Summary of the Invention
[0009] Embodiments of the present disclosure include an electrochemiluminescence (ECL) detection method comprising:
[0010] a) providing a substrate comprising an electrode and having a binding reagent immobilized on a surface of the substrate;
[0011] b) contacting the substrate with a composition comprising:
[0012] i) a binding partner and / or a binding complex, said binding partner and / or binding complex comprising an oligonucleotide, wherein said binding agent binds to said binding partner and / or binding complex;
[0013] ii) a plurality of ECL-labeled oligonucleotide probes comprising oligonucleotide sequences complementary to the oligonucleotide sequences of the binding partners and / or the oligonucleotides of the binding complex; and
[0014] iii) an ECL co-reactant, wherein the ECL co-reactant is not TPA;
[0015] c) allowing a portion of the plurality of ECL-labeled oligonucleotide probes to hybridize to the binding partner and / or the oligonucleotide of the binding complex, wherein the binding partner and / or the binding complex is bound by the binding reagent, and wherein another portion of the plurality of ECL-labeled oligonucleotide probes does not hybridize to the binding partner and / or the oligonucleotide of the binding complex bound by the binding reagent;
[0016] d) selectively dequenching the portion of the plurality of ECL-labeled probes that are hybridized to the binding partner and / or the oligonucleotide-bound complex;
[0017] e) applying a voltage to the electrodes to generate ECL; and
[0018] f) measuring said ECL, wherein said portion of said plurality of ECL-labeled oligonucleotide probes that are not hybridized to said binding partner and / or said oligonucleotide bound complex is not removed from said composition prior to applying said voltage and measuring said ECL.
[0019] In an embodiment, b) contacting the substrate with the composition comprises:
[0020] b') contacting the substrate with a composition comprising the binding partner and / or binding complex;
[0021] b″) contacting the substrate with a composition comprising the plurality of ECL-labeled oligonucleotide probes; and
[0022] b'") contacting the substrate with a composition comprising the ECL co-reactant.
[0023] In an embodiment, each of steps b'), b") and b'") is performed sequentially. In an embodiment, at least two of steps b'), b") and b'") are performed simultaneously. In an embodiment, the method comprises:
[0024] b') contacting the substrate with a first composition comprising the binding partner and / or binding complex and allowing the binding partner and / or binding complex to be immobilized on the surface by binding to the binding reagent; and
[0025] b″) contacting the substrate comprising the immobilized binding partner and / or binding complex with a second composition comprising the plurality of ECL-labeled oligonucleotide probes and the ECL co-reactant; or
[0026] b′) contacting the substrate with a first composition comprising the binding partner and / or binding complex and the plurality of ECL-labeled oligonucleotide probes, wherein a portion of the plurality of ECL-labeled oligonucleotide probes hybridizes with the oligonucleotides of the binding partner and / or binding complex, and allowing the binding partner and / or binding complex to be immobilized on the surface by binding to the binding reagent; and
[0027] b″) contacting the substrate comprising the immobilized binding partner and / or binding complex with a second composition comprising the ECL co-reactant; or
[0028] b') contacting the substrate with a first composition comprising the binding partner and / or binding complex and allowing the binding partner and / or binding complex to be immobilized on the surface by binding to the binding reagent; and
[0029] b″) contacting the substrate comprising the immobilized binding partner and / or binding complex with a second composition comprising the plurality of ECL-labeled oligonucleotide probes, and allowing a portion of the plurality of ECL-labeled oligonucleotide probes to hybridize with the oligonucleotides of the immobilized binding partner and / or binding complex; and
[0030] b'") contacting the substrate with a third composition comprising the ECL co-reactant.
[0031] In an embodiment, it further comprises washing the substrate after contacting the substrate with the binding partner and / or binding complex to remove the binding partner and / or binding complex not bound by the binding reagent, wherein the washing is performed before contacting the substrate with the composition comprising the plurality of ECL-labeled oligonucleotide probes.
[0032] Embodiments of the present disclosure include an electrochemiluminescence (ECL) detection method comprising:
[0033] a) providing a substrate comprising an electrode and having a binding partner and / or binding complex comprising an oligonucleotide immobilized on the surface of the substrate;
[0034] b) contacting the substrate with a composition comprising:
[0035] i) a plurality of ECL-labeled oligonucleotide probes comprising oligonucleotide sequences complementary to the oligonucleotide sequences of the binding partners and / or the oligonucleotides of the binding complex; and
[0036] ii) an ECL co-reactant, wherein the ECL co-reactant is not TPA;
[0037] c) allowing a portion of the plurality of ECL-labeled oligonucleotide probes to hybridize to the immobilized binding partner and / or the oligonucleotide bound to the complex, and wherein another portion of the plurality of ECL-labeled oligonucleotide probes does not hybridize to the immobilized binding partner and / or the oligonucleotide bound to the complex;
[0038] d) selectively dequenching the portion of the plurality of ECL-labeled probes that are hybridized to the binding partner and / or the oligonucleotide-bound complex;
[0039] e) applying a voltage to the electrodes to generate ECL; and
[0040] f) measuring said ECL, wherein said portion of said plurality of ECL-labeled oligonucleotide probes that are not hybridized to said binding partner and / or said oligonucleotide bound complex is not removed from said composition prior to applying said voltage and measuring said ECL.
[0041] In an embodiment, b) contacting the substrate with the composition comprises:
[0042] b') contacting the substrate with a composition comprising the plurality of ECL-labeled oligonucleotide probes; and
[0043] b") contacting the substrate with a composition comprising the ECL co-reactant.
[0044] In embodiments, each of steps b') and b") is performed sequentially. In embodiments, each of steps b') and b") is performed simultaneously, optionally wherein said plurality of ECL-labeled oligonucleotide probes and said ECL co-reactants are in a single composition.
[0045] Embodiments of the present disclosure, including the embodiments in the preceding paragraphs, include embodiments in which the binding partner and / or binding complex comprises an analyte. In embodiments, the analyte comprises a peptide. In embodiments, the analyte comprises an oligonucleotide. In embodiments, the analyte is the oligonucleotide of the binding partner and / or binding complex. In embodiments, the analyte is labeled with the oligonucleotide. In embodiments, the analyte is labeled with the oligonucleotide by binding the analyte to a detection reagent comprising the oligonucleotide. In embodiments, the oligonucleotide of the binding partner and / or binding complex comprises multiple copies of the sequence complementary to the oligonucleotide sequence of the multiple ECL-labeled oligonucleotide probes. In embodiments, prior to contacting the substrate with the multiple ECL-labeled oligonucleotide probes, an amplification reaction is performed to produce the multiple copies of the sequence complementary to the oligonucleotide sequence of the multiple ECL-labeled oligonucleotide probes. In an embodiment, the analyte is labeled with the oligonucleotide by binding the analyte to a detection reagent comprising an oligonucleotide primer, and wherein the oligonucleotide primer is extended by a polymerase to produce oligonucleotides comprising the multiple copies of the sequence complementary to the oligonucleotide sequence of the ECL-labeled oligonucleotide probe. In an embodiment, the amplification reaction or primer extension is a rolling circle amplification reaction. In an embodiment, the ECL-labeled oligonucleotide probe comprises a stem-loop or hairpin structure, an ECL label and a quenching portion, wherein the quenching portion is adjacent to the ECL label and quenches the ECL label when the oligonucleotide probe is in a stem-loop or hairpin configuration, but does not quench the ECL label when the stem-loop or hairpin structure is in an open configuration, and wherein the selective dequenching comprises hybridizing the portion of the multiple ECL-labeled oligonucleotide probes to the binding partner and / or the oligonucleotide of the binding complex in the open configuration. In an embodiment, the ECL-labeled oligonucleotide probe comprises an ECL label and a quenching portion, wherein the quenching portion is proximal to the ECL label and quenches the ECL label when the oligonucleotide probe is linearly confirmed, wherein the selective dequenching comprises selectively cleaving the quenching portion from only the portion of the multiple ECL-labeled probes that hybridizes with the oligonucleotide of the binding partner and / or binding complex, such that the quenching portion is released into the solution and is no longer proximal to the ECL label of the hybridized ECL-labeled probe, and after cleavage of the quenching portion, the hybridized ECL-labeled probe remains hybridized with the oligonucleotide of the binding partner and / or binding complex. In an embodiment, the cleavage is performed by an enzyme. In an embodiment, the enzyme is selected from the group consisting of: a nicking restriction endonuclease, an RNase H2, and a polymerase with 5' exonuclease activity.In an embodiment, the enzyme only cuts the ECL-labeled oligonucleotide probe, thereby leaving the oligonucleotide of the binding partner and / or binding complex intact. In an embodiment, the enzyme is a nicking restriction endonuclease that recognizes a sequence in the hybridized ECL-labeled probe, or an RNase H2 that recognizes RNA bases in the hybridized ECL-labeled probe. In an embodiment, the enzyme is a polymerase with 5' exonuclease activity, and wherein the method further comprises: hybridizing a primer to the oligonucleotide of the binding partner and / or binding complex at position 5' of the hybridized ECL-labeled probe, allowing the polymerase with 5' exonuclease activity to extend the primer to the hybridized ECL-labeled probe, wherein the 5' exonuclease activity cuts the quenching portion of the hybridized ECL-labeled probe, and wherein the ECL-labeled probe includes a portion that is resistant to the 5' exonuclease activity.In an embodiment, the ECL coreactant is selected from the group consisting of: 3-(di-n-propylamino)-propanesulfonic acid; 4-(di-n-propylamino)-butanesulfonic acid; 4-[bis-(2-hydroxyethane)-amino]-butanesulfonic acid; piperidine-N-(3-propanesulfonic acid); azepane-N-(3-propanesulfonic acid); piperidine-N-(3-propionic acid) (PPA); 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO); 3-morpholinopropanesulfonic acid (MOPS); N-(2-hydroxyethyl)piperazine- N'-3-propanesulfonic acid (EPPS); N-(2-hydroxyethyl)piperazine-N'-3-ethanesulfonic acid (BES); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); triethanolamine (TEA); N-2-hydroxypiperazine-N-2-ethanesulfonic acid (HEPES); piperazine-N,N'-bis-4-butanesulfonic acid; homopiperidinyl-N-3-propanesulfonic acid; piperazine-N,N'-bis-3-propanesulfonic acid; piperazine-N-3-propanesulfonic acid; piperazine-N-2-hydroxyethane-N'-3 -methylpropionate; piperazine-N,N'-bis-3-methylpropionate; 1,6-diaminohexane-N,N,N',N'-tetraacetic acid; N,N-dipropyl-N-4-aminobutanesulfonic acid; N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); 1,3-bis[tris(hydroxymethyl)methylamino]propane (bis-trispropane); 3-dimethylamino-1-propanol; 3-dimethylamino-2-propanol; N,N,N',N'-tetrapropylpropane-1,3-diamine (TPA dimer); piperazine-N,N'-bis(2-hydroxypropane)sulfonic acid (POPSO) and 2-hydroxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid (HEPPSO), n-butyldiethanolamine (BDEA), 2-dibutylaminoethanol (DBAE), tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS), and combinations thereof. In an embodiment, the ECL co-reactant is TEA, or is selected from the group consisting of TEA, tBDEA, BDEA, MDEA, DEA-PS, and combinations thereof; selected from the group consisting of TEA, tBDEA, MDEA, DEA-PS, and combinations thereof; or selected from the group consisting of TEA, tBDEA, MDEA, DEA-PS, and combinations thereof.In an embodiment, the quenching moiety is selected from the group consisting of ATTO 540Q, ATTO 575Q, ATTO 580Q, ATTO 612Q, Iowa Black FQ, Iowa Back RQ, QSY 21, IRDye QC-1, BHQ0, BHQ1, BHQ-2, BHQ-3, Dabcyl, QSY 7, QSY 9, QSY 21, QSY 35, QXL 490, QXL520, QXL 570, QXL 670, ferrocene, iron bipyridine, and combinations thereof. In an embodiment, the ECL label is an organometallic complex comprising ruthenium, osmium, iridium, rhenium, and / or a lanthanide metal. The ECL label comprises tris(bipyridine)ruthenium or modified tris(bipyridine)ruthenium. The ECL label comprises the chemical structure shown in Formula II:
[0046] In an embodiment, the co-reactant is in a composition according to any one of the embodiments above and herein. In an embodiment, the co-reactant is in a composition according to any one of numbered items 1 to 69. In an embodiment, the co-reactant comprises TEA. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] The following drawings constitute part of this specification and are included to further illustrate exemplary embodiments of certain aspects of the present disclosure.
[0048] Figure 1A and 1B Reference is made to Example 1 and shows results from an example of an ECL-based assay. In a solid surface ECL assay, a panel of ECL co-reactants bound to one of two surfactants was tested for ECL production and the ability to distinguish between surface-bound ("BTI") and free (in solution; "FT") ECL label. Figure 1A Shown are the ECL signals measured with BTI, FT, and the background signal ("D100") measured with ECL read buffer only (no label). Figure 1B Shown are the ratio of the ECL signal from the bound label to the ECL signal from the free label ("BTI / FT") and the signal to background ratio ("S / B").
[0049] Figures 2A-2C Refers to Example 2 and shows the results of an example of an ECL-based assay. Figure 2A Shown are graphs of the ECL generated by BTI and FT, and the BTI / FT ratio with different concentrations of TEA. Figure 2B Shown are the measured ECL signals from BTI, FT and background (D100) with different concentrations of TEA. Figure 2CShown are the BTI / FT ratio, S / B ratio, and percent ECL generation compared to PIPES ECL read buffer.
[0050] Figure 3A and 3B Refers to Example 3 and shows the results of an example of an ECL-based assay. Figure 3A Shown are the changes in ECL signal as a function of PIPES concentration. Figure 3B Shown are the changes in ECL signal as a function of PIPES or TEA concentration.
[0051] Figures 4A-4H Examples of ECL-based assays described herein are presented and further described in Example 4.
[0052] Figure 4A A "standard" 2-step wash assay is shown in which a capture antibody ("cAb"; binding reagent) immobilized on a surface is contacted with a mixture of analytes, one of which specifically binds to the capture antibody, and the surface is then washed, resulting in capture of the analyte on the surface. A mixture of detection antibodies ("dAb"; detection reagents), each containing an ECL label and one of which specifically binds to the analyte, is then added to the surface, and the surface is then washed, generating a bound complex comprising the cAb, analyte, and dAb. ECL reading buffer is then added to the surface, and the resulting ECL is then read by an ECL reader instrument.
[0053] Figure 4B A "1-step" assay is demonstrated in which the capture antibody on the surface is contacted with the analyte mixture and then Figure 4A The surface was washed as shown. The detection antibody mixture was then added, followed by the addition of ECL read buffer without washing between the addition of the detection antibody mixture and the ECL read buffer. The resulting ECL was then read by an ECL reader instrument.
[0054] Figure 4C A "1-step no-wash" assay is demonstrated, in which the capture antibody on the surface is contacted with the following: an analyte mixture and a detection antibody mixture, followed by contact with ECL reading buffer without washing between any steps. The resulting ECL is then read by an ECL reader instrument.
[0055] Figure 4D A "mimetic ECL labeling" assay is presented, in which a capture antibody on a surface is contacted with an analyte mixture, the surface is washed, and a detection antibody mixture is added, and the surface is optionally washed again, resulting in a Figure 4AThe bound complex shown. ECL reading buffer is then added to the surface along with a detection antibody that includes the ECL label and does not bind to any component of the bound complex on the surface, which acts as a surrogate for the "free" ECL label in solution. The resulting ECL is then read by an ECL reader instrument.
[0056] Figure 4E A multiplex version of a "standard" 2-step wash assay is shown, in which one or more surfaces include multiple binding domains, each of which includes a capture antibody that can bind to an analyte in an analyte mixture. After adding the analyte mixture, the surface including the binding domain is washed, resulting in the capture of multiple analytes on the binding domain. A mixture of detection antibodies, each containing an ECL label and capable of binding to an analyte in the analyte mixture, is then added to the surface, and the surface is then washed, generating multiple binding complexes, each of which includes a cAb, an analyte, and a dAb. ECL reading buffer is then added to the surface, and the resulting ECL is read by an ECL instrument.
[0057] Figure 4F A multiplexed version of a "1-step" assay is presented, wherein one or more surfaces comprise multiple binding domains, each comprising a capture antibody that can bind to an analyte in an analyte mixture. Figure 4E As shown, the surface including the binding domain is washed after adding the analyte mixture. A detection antibody mixture is added to form a plurality of binding complexes, and then an ECL read buffer is added between the addition of the detection antibody mixture and the ECL read buffer without washing. The resulting ECL is then read by an ECL reader instrument.
[0058] Figure 4G A multiplexed version of a "1-step no-wash" assay was demonstrated, in which one or more surfaces comprise multiple binding domains, each comprising a capture antibody that can bind to an analyte in an analyte mixture. The surfaces comprising the binding domains are contacted with the analyte mixture and a mixture of detection antibodies to form multiple binding complexes, and then ECL read buffer is added between any steps without washing. The resulting ECL is then read by an ECL reader instrument.
[0059] Figure 4H A multiplexed version of an "analog ECL labeling" assay is presented, wherein one or more surfaces comprise a plurality of binding domains, each comprising a capture antibody that can bind to an analyte in an analyte mixture. The surface comprising the binding reagent is contacted with the analyte mixture, the surface is washed, a detection antibody cocktail is added, and the surface is optionally washed again, resulting in a multiplexed version of an "analog ECL labeling" assay. Figure 4EThe multiple binding complexes shown are shown. ECL reading buffer is then added to the surface along with a detection antibody that includes an ECL label and does not bind to any component of the binding complexes on the surface, which acts as a surrogate for the "free" ECL label in solution. The resulting ECL is then read by an ECL reader instrument.
[0060] Figures 5A-5D Refers to Example 5A and shows the results of an example of an ECL-based assay. Figure 5A Results from three different multiplex assay formats (e.g. Figure 4E 、 4F Specific ECL signals and nonspecific binding (NSB) results with BDEA, PIPES, and TEA read buffers (shown in 4H and 4H). Figure 5B Shown Figure 5A The lowest limit of detection (LLOD) was determined. Figure 5C Shown from Figure 5A Relative comparison of ECL and NSB results. Figure 5D Shown is a comparison of signal-to-background (S / B) and signal-to-noise (S / N) ratios across all ECL read buffers and assay formats.
[0061] Figures 6A-6C Refers to Example 5B and shows the results of an example of an ECL-based assay. Figure 6A Results from three different multiplex assay formats (e.g. Figure 4E 、 4F and 4G ) with BDEA, PIPES, and TEA read buffers for specific ECL signals and nonspecific binding (NSB) results. Figure 6B Shown Figure 6A The lowest limit of detection (LLOD) was determined. Figure 6C Shown from Figure 6A Relative comparison of ECL and NSB results.
[0062] Figures 7A-11B Refers to Example 6 and shows the results of an example of an ECL-based assay.
[0063] Figure 7A Shown is a list of sample matrices tested in the 1-step no-wash ECL assay with TEA read buffer. Figure 7B Shows the addition to Figure 7A List of interferents in the sample matrix that will be tested in the 1-step no-wash ECL assay with TEA read buffer.
[0064] Figure 8AResults are shown for ECL signals generated from TEA read buffer with bound ECL label ("bound") and free ECL label ("free"), where different sample matrices were mixed with diluent. "H2O" represents the signal from a control where water was substituted for the sample matrix before the TEA read buffer. The column heading with "free" represents 6 nM free ECL label in the diluent. Figure 8B The normalized ECL signal is shown relative to the ECL signal generated from an assay in which no sample matrix was added. Figure 8A results.
[0065] Figure 9A Shown are the results of ECL signals generated from TEA read buffer with bound and free ECL labels containing different interferents in different sample matrices. Figure 9B The normalized ECL signal is shown relative to the ECL signal generated from an assay in which no sample matrix and interferents were added. Figure 9A results.
[0066] Figure 10A Results are shown for ECL signals generated from TEA read buffer with free ECL label ("D3+STAG") in different sample matrices. The column heading with "Free" indicates 240 nM free ECL label in diluent. Figure 10B The normalized ECL signal is shown relative to the ECL signal generated from an assay in which no sample matrix was added. Figure 10A results.
[0067] Figure 11A Shown are the results of ECL signals generated from TEA read buffer with 240 nM free ECL in different sample matrices with different interferents. Figure 11B The normalized ECL signal is shown relative to the ECL signal generated from an assay in which no sample matrix and interferents were added. Figure 11A results.
[0068] Figure 12 Reference is made to Example 7 and shows the results of an example of an ECL-based assay. The combination of ECL co-reactants described in Example 1 was tested in an ECL-based assay. Figure 12 The upper right side of the graph shows the ECL signal generated by BTI, while Figure 12 The lower left side of the graph in shows the ECL signal ratio of the mixed ECL co-reactant to the sum of the signals generated by the individual ECL co-reactants.
[0069] Figure 13A and 13B This relates to Example 8 and shows the results of an example of an ECL-based assay. The ECL co-reactants described in Example 1 were tested for TRITON TMSensitivity to the presence of X-100. Figure 13A Showing Triton TM ECL signals from BTI and FT for each ECL reactant in X-100 (TX100) and PEG (18) tridecyl ether (PEG18TDE). Figure 13B Showing Triton TM Ratio of ECL generated in X-100 relative to PEG(18) tridecyl ether.
[0070] Figure 14 is a schematic representation of an embodiment of a method for detecting a target oligonucleotide analyte using an ECL-labeled molecular beacon oligonucleotide probe and a co-reactant (co-reactant not shown).
[0071] Figure 15 is a schematic representation of an embodiment of a method for detecting a target oligonucleotide analyte using an ECL-labeled molecular beacon oligonucleotide probe and a TEA co-reactant (co-reactant not shown) as described in Examples 10-12.
[0072] Figure 16 is a diagrammatic representation of an example of an ECL-labeled molecular beacon probe prepared in Example 9 and used in the experiments described in Examples 10-12.
[0073] Figures 17A-17D is a graphical representation of the results of an embodiment of a no-wash experiment described in Example 10 using the ECL-labeled molecular beacon probe of Example 9. Figure 17A Depicted are ECL signals at increasing concentrations of free target oligonucleotide in solution using a read buffer containing TPA. Figure 17B Depicted are ECL signals in the presence of increasing concentrations of target oligonucleotides immobilized on the substrate surface using a read buffer containing TPA. Figure 17C Depicted are ECL signals at increasing concentrations of free target oligonucleotide in solution using a read buffer containing TEA. Figure 17D Depicted are ECL signals in the presence of increasing concentrations of target oligonucleotides immobilized on the substrate surface using a read buffer containing TEA.
[0074] Figures 18A-18B Results of an embodiment of a no-wash, wide concentration range experiment using the ECL-labeled molecular beacon probe of Example 9 described in Example 11 are reported. Figure 18A Depicted are ECL signals in the presence of increasing concentrations of target oligonucleotides immobilized on the substrate surface using a read buffer containing TEA. Figure 18B is listed Figure 18A Depicted in Figure 5 are graphs of the ECL signal intensity for each MB probe at decreasing target oligonucleotide concentrations.
[0075] Figures 19A-19B Results of an embodiment of a 2-step no-wash experiment using the ECL-labeled molecular beacon probe of Example 9 described in Example 12 are reported. Figure 19A Depicted are ECL signals in the presence of increasing concentrations of target oligonucleotides immobilized on the substrate surface using a read buffer containing TEA. Figure 19B is listed Figure 18A Depicted in Figure 5 are graphs of the ECL signal intensity for each MB probe at decreasing target oligonucleotide concentrations.
[0076] Figure 20 is a diagram of an embodiment of a method for detecting peptide analytes indirectly labeled with oligonucleotide primers, wherein the method utilizes an ECL-labeled molecular beacon oligonucleotide probe that binds to an extended sequence derived from the primer. No wash step is performed after adding the ECL-labeled oligonucleotide probe. In this embodiment, streptavidin is the binding reagent, and a biotinylated capture antibody, the peptide analyte, and a secondary antibody comprising an extended oligonucleotide primer together form a binding complex.
[0077] Figure 21 is a diagram of an embodiment of a method for detecting a target oligonucleotide analyte using an ECL-labeled oligonucleotide probe, wherein a quenching portion is selectively cleaved from the hybridization probe by an enzyme (e.g., a nicking endonuclease), dequenching the ECL label of the probe while allowing the remaining portion of the ECL-labeled probe to hybridize to the target oligonucleotide. DETAILED DESCRIPTION
[0078] The ECL co-reactants disclosed herein provide consistent ECL production across different assay formats. It has been found that the compositions herein (e.g., compositions comprising triethanolamine (TEA)) are useful in ECL-based assays that do not require a wash step. Many ECL-based assays performed on solid surfaces involve at least one wash step to remove unbound ECL markers prior to detecting the ECL markers on the surface (i.e., a "wash" assay). The wash step can be eliminated if the detection method can effectively distinguish between ECL markers bound to the surface (e.g., as part of a binding complex to be detected) or unbound "free" ECL markers in solution. "No-wash" assay formats that eliminate wash steps are generally advantageous because wash steps can be difficult or cumbersome to perform in many cases. However, no-wash assay formats are generally difficult to develop due to the high background ECL signal resulting from incomplete differentiation of free ECL markers present in the reaction mixture relative to bound ECL markers.
[0079] In ECL-based assays performed on solid surfaces, it was surprisingly found that triethanolamine (TEA) can highly discriminate between unbound ("free") ECL label in solution versus surface-bound ECL label. The compositions described herein that include TEA increase the ratio of ECL signal from bound label to ECL signal from free label relative to compositions that include conventional co-reactants such as tripropylamine (TPA). Thus, the compositions herein provide improved assay performance, particularly when measuring low-affinity interactions, which require the presence of high concentrations of ECL label in the reaction but are also expected to suffer significant signal loss due to dissociation of the binding complex during the wash steps.
[0080] The ECL signals generated by the compositions herein, e.g., compositions comprising TEA, tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), and / or 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS), provide additional advantages, such as improved consistency of performance between compositions that differ based on the presence or absence of surfactants or based on the identity of the surfactants. Specifically, the ... DEA-PS, provide additional advantages, such as improved consistency of performance between compositions that differ based on the presence or absence of surfactants or based on the identity of the surfactants, provide additional advantages, such as improved consistency of performance between compositions TM Thus, harsh surfactants (e.g., TRITON TM X-100, which disrupts the lipid bilayer membrane of a portion of certain analytes of interest (such as whole cells or extracellular vesicles), which is different from tripropylamine (TPA, which usually requires TRITON TM X-100 is used as a typical ECL co-reactant to produce the best ECL. Therefore, the compositions herein can be used in assays for detecting analytes that are sensitive to irritating surfactants. In addition, the ECL co-reactant ECL signal is not greatly affected by the presence of different surfactants, and therefore, these ECL co-reactants are versatile and can be easily incorporated into different formulations while maintaining their ECL generating ability.
[0081] Thus, the compositions herein, eg, compositions comprising TEA, tBDEA, MDEA, and / or DEA-PS, advantageously expand the types of ECL-based assays that can be performed.
[0082] Unless otherwise defined herein, the scientific and technical terms used in this disclosure should have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context otherwise requires, singular terms should include the plural, and plural terms should include the singular. The articles "a / an" are used herein to refer to one or more than one (i.e., at least one) grammatical object of the article. For example, "element" means one element or more than one element.
[0083] Use of the term "or" in the claims is intended to mean "and / or" unless explicitly stated to refer only to alternatives or the alternatives are mutually exclusive, although this disclosure supports definitions referring only to alternatives and to "and / or."
[0084] As used herein, the terms "comprising" (and any variations or forms of comprising, such as "comprise" and "comprises"), "having" (and any variations or forms of having, such as "have" and "has"), "including" (and any variations or forms of containing, such as "includes" and "include"), or "containing" (and any variations or forms of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0085] The use of the term "for example" and its corresponding abbreviation "eg" (whether italicized or not) means that the specific term referenced is a representative example and embodiment of the present disclosure, and unless otherwise expressly stated, the representative examples and embodiments are not intended to be limited to the specific example referenced or referenced.
[0086] As used herein, "between ... " is a range that includes the ends of a range. For example, the number between x and y clearly includes the numbers x and y and any number (including fractions and integers) that falls within x and y. In addition, the range of "5 to 10" mentioned herein includes integers 5, 6, 7, 8, 9 and 10, and fractions 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, etc. Reference to any numerical range clearly includes each numerical value (including fractions and integers) encompassed by the range. For illustration, the range of "at least 50" or "at least about 50" includes integers 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, etc., and fractions 50.1, 50.2, 50.3, 50.4, 50.5, 50.6, 50.7, 50.8, 50.9, etc. In further detail, the range of "less than 50" or "less than about 50" mentioned herein includes integers 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, etc., as well as fractions 49.9, 49.8, 49.7, 49.6, 49.5, 49.4, 49.3, 49.2, 49.1, 49.0, etc.
[0087] As used herein, the terms "substantially" or "essentially" are also applicable when used in a negative sense to refer to the complete or almost complete absence of an action, characteristic, property, state, structure, item, or result. For example, a "substantially" flat surface is either a completely flat surface or a nearly flat surface, the effect of which would be the same as that of a completely flat surface. In another example, a composition that is "substantially" free of a component would not contain any amount of the component, or the amount of the component in the composition would be so low that the effect would be the same as if the component were not present.
[0088] In an embodiment, the present disclosure provides a composition comprising: (a) triethanolamine (TEA); and (b) an ionic component; wherein the pH of the composition is about 7.0 to about 8.0, and wherein the composition is substantially free of additional pH buffering components.
[0089] In an embodiment, the present disclosure provides a composition comprising: (a) triethanolamine (TEA); (b) an ionic component; and (c) an ECL-labeled component; wherein the pH of the composition is about 7.0 to about 8.0, and wherein the composition is substantially free of an additional pH buffering component.
[0090] In an embodiment, the present disclosure provides a composition comprising: (a) about 1000 mM to about 6500 mM triethanolamine (TEA); and (b) about 500 mM to about 2000 mM of an ionic component; wherein the pH of the composition is about 7.0 to about 8.0.
[0091] In an embodiment, the present disclosure provides a composition comprising: (a) triethanolamine (TEA); (b) an ionic component; (c) an alkyl ether-polyethylene glycol (PEG); wherein the pH of the composition is about 7.0 to about 8.0.
[0092] In an embodiment, the present disclosure provides a composition comprising (a) TEA, (b) an ionic component; and (c) optionally, one or both of an ECL-labeled component and a surfactant, wherein the pH of the composition is from about 7.0 to about 8.0, and optionally wherein the composition is substantially free of additional pH buffering components.
[0093] In an embodiment, the present disclosure provides a composition comprising: (a) an electrochemiluminescent (ECL) co-reactant selected from N-tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS) and combinations thereof; (b) an ionic component; and (c) a surfactant; wherein the pH of the composition is about 7.0 to about 8.0.
[0094] In embodiments, the present disclosure provides compositions consisting of or consisting essentially of the recited components in the recited amounts. In compositions consisting essentially of the recited components, such compositions specifically do not include components that substantially affect the ECL generating properties of the composition. The ECL generating properties of a composition can be determined by methods known to those skilled in the art. For example, a composition can be contacted with a known number of ECL labels on an electrode and a voltage applied to the electrode, thereby generating ECL. In embodiments, "substantially unaffected" ECL generating properties means that a composition consisting "essentially of" the recited components generates about 80%, about 90%, about 95%, about 98%, about 99%, about 100%, about 101%, about 102%, about 105%, about 110%, or about 120% ECL as a composition "consisting" of the recited components. In embodiments, a composition consisting essentially of the recited components specifically does not include additional ECL generating compounds, for example, additional ECL co-reactants.
[0095] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) triethanolamine (TEA); (b) an ionic component; and (c) a surfactant; wherein the pH of the composition is from about 7.0 to about 8.0, and wherein the composition is substantially free of additional pH buffering components. In an embodiment, the present disclosure provides a composition consisting of: (a) triethanolamine (TEA); (b) an ionic component; and (c) a surfactant; wherein the pH of the composition is from about 7.0 to about 8.0, and wherein the composition is substantially free of additional pH buffering components.
[0096] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) triethanolamine (TEA); (b) an ionic component; (c) a surfactant; and (d) an ECL-labeled component, wherein the pH of the composition is from about 7.0 to about 8.0, and wherein the composition is substantially free of an additional pH buffering component. In an embodiment, the present disclosure provides a composition consisting of: (a) triethanolamine (TEA); (b) an ionic component; (c) a surfactant; and (d) an ECL-labeled component; wherein the pH of the composition is from about 7.0 to about 8.0.
[0097] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) about 1000 mM to about 6500 mM triethanolamine (TEA); (b) about 500 mM to about 2000 mM ionic component; and (c) a surfactant; wherein the pH of the composition is about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition consisting of: (a) about 1000 mM to about 6500 mM triethanolamine (TEA); (b) about 500 mM to about 2000 mM ionic component; and (c) a surfactant; wherein the pH of the composition is about 7.0 to about 8.0.
[0098] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) about 1000 mM to about 6500 mM triethanolamine (TEA); (b) about 500 mM to about 2000 mM of an ionic component; (c) a surfactant; and (d) an ECL-labeled component; wherein the pH of the composition is about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition consisting of: (a) about 1000 mM to about 6500 mM triethanolamine (TEA); (b) about 500 mM to about 2000 mM of an ionic component; (c) a surfactant; and (d) an ECL-labeled component; wherein the pH of the composition is about 7.0 to about 8.0.
[0099] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) triethanolamine (TEA); (b) an ionic component; (c) an alkyl ether-polyethylene glycol (PEG); wherein the pH of the composition is from about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition consisting of: (a) triethanolamine (TEA); (b) an ionic component; (c) an alkyl ether-polyethylene glycol (PEG); wherein the pH of the composition is from about 7.0 to about 8.0.
[0100] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) triethanolamine (TEA); (b) an ionic component; (c) an alkyl ether-PEG; and (d) an ECL-labeled component; wherein the pH of the composition is from about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition consisting of: (a) triethanolamine (TEA); (b) an ionic component; (c) an alkyl ether-PEG; and (d) an ECL-labeled component; wherein the pH of the composition is from about 7.0 to about 8.0.
[0101] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) an electrochemiluminescent (ECL) co-reactant selected from the group consisting of N-tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS), and combinations thereof; (b) an ionic component; (c) a surfactant; and (d) a pH buffering component, wherein the pH of the composition is from about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition consisting of: (a) an electrochemiluminescent (ECL) co-reactant selected from the group consisting of N-tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS), and combinations thereof; (b) an ionic component; (c) a surfactant; and (d) a pH buffering component, wherein the pH of the composition is from about 7.0 to about 8.0.
[0102] In an embodiment, the present disclosure provides a composition consisting essentially of: (a) an ECL co-reactant selected from the group consisting of tBDEA, MDEA, DEA-PS, and combinations thereof; (b) an ionic component; (c) a surfactant; (d) a pH buffering component, and (e) an ECL labeled component, wherein the pH of the composition is from about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition consisting of: (a) an ECL co-reactant selected from the group consisting of tBDEA, MDEA, DEA-PS, and combinations thereof; (b) an ionic component; (c) a surfactant; (d) a pH buffering component, and (e) an ECL labeled component, wherein the pH of the composition is from about 7.0 to about 8.0.
[0103] As discussed herein, the ECL co-reactants herein advantageously provide consistent ECL production across different assay formats (e.g., wash and no-wash assays) and are combined with different classes of surfactants (e.g., mild surfactants that do not disrupt lipid bilayer membranes and harsher surfactants that can disrupt lipid bilayer membranes). Thus, compositions comprising the ECL co-reactants herein (also referred to as "ECL read buffers") can be used in a wide range of ECL-based binding assays.
[0104] In an embodiment, the ECL co-reactant comprises a tertiary amine. In an embodiment, the ECL co-reactant comprises a tertiary alkylamine. In an embodiment, the ECL co-reactant comprises a tertiary hydroxyalkylamine. In an embodiment, the ECL co-reactant comprises a zwitterionic tertiary amine. In an embodiment, the ECL co-reactant comprises a secondary amine. In an embodiment, the ECL coreactant is tributylamine (TBA), (dibutyl)aminoethanol (DBAE), (diethyl)aminoethanol (DEAE), triethanolamine (TEA), butyldiethanolamine (BDEA), propyldiethanolamine (PDEA), ethyldiethanolamine (EDEA), methyldiethanolamine (MDEA), tert-butyldiethanolamine (tBDEA), dibutylamine (DBA), butylethanolamine (BEA), diethanolamine (DEA), dibutylamine propyl sulfonate (DBA-PS), dibutylamine butyl sulfonate (DBA-BS), butylethanolamine propyl sulfonate (BEA-PS), butylethanolamine butyl sulfonate (BEA-BS), diethanolamine propyl sulfonate (also known as 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid; DEA-PS), or diethanolamine butyl sulfonate (DEA-BS). The structures of exemplary ECL coreactants described herein are shown below.
[0105]
[0106]
[0107] Triethanolamine ECL coreactant
[0108] The present disclosure provides a composition including an ECL coreactant. In an embodiment, the ECL coreactant is triethanolamine (TEA). As discussed herein, it was found that TEA provides favorable ECL generation properties in non-washing binding assays. In the assay of capturing and detecting species of interest (e.g., analyte or binding complex described herein) on a solid surface, TEA can distinguish between "free" ECL labels that are not part of the species to be detected (e.g., analyte or binding complex) and "bound" ECL labels that are part of the species bound to the surface (e.g., analyte or binding complex). The non-washing binding assay utilizing TEA as an ECL coreactant reduces the non-specific ECL from the ECL label to the species to be detected, thereby reducing background ECL and increasing the signal-to-background ratio of the assay. In an embodiment, the signal-to-background ratio of the non-washing assay using TEA as an ECL coreactant is 2 times, 3 times, 4 times, 5 times or 10 times that of the assay using tripropylamine (TPA) or piperazine-N, N'-bis(2-ethanesulfonic acid) (PIPES) as an ECL coreactant. In embodiments, the limit of detection of a no-wash assay using TEA as an ECL co-reactant is 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 10, 1 / 20, or 1 / 40 lower than the limit of detection of an assay using TPA or PIPES as an ECL co-reactant.
[0109] Another advantage of TEA as an ECL co-reactant is that TEA is insensitive to sample matrices and / or interfering substances. This is particularly beneficial in the context of non-wash assays, in which the reaction mixture may contain a matrix from human or animal origin (e.g., containing proteins, cellular components and debris, culture medium, etc.), which may also contain metabolites and / or drug interfering substances (e.g., acetaminophen, ibuprofen, naproxen, salicylic acid, and / or tolbutamine). In an embodiment, TEA generates substantially the same ECL signal in a reaction mixture comprising one or more sample matrices and / or one or more interfering substances as in a reaction mixture not comprising a sample matrix and / or interfering substances.
[0110] It was further discovered that TEA provides the benefit of producing a consistent ECL signal when used in the absence of a surfactant, or when used in combination with different types of surfactants (e.g., the irritating surfactants and mild surfactants described herein). As used herein, an "irritating" surfactant is capable of disrupting, lysing, and / or dissolving lipid bilayer membranes (e.g., cell membranes or extracellular vesicles (EVs)). In contrast, a "mild" surfactant does not disrupt, lyse, or dissolve lipid bilayer membranes. In embodiments, a composition comprising TEA and an irritating surfactant, except that a mild surfactant is present instead of an irritating surfactant, produces an ECL signal substantially similar to a composition comprising the same components when subjected to the same conditions for producing ECL (e.g., voltage waveform, electrode type, amount of composition, amount of ECL labeling, etc.). In embodiments, the irritating surfactant is TRITON TM X-100, TRITON TM X-114, NP-40, CA-630, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS) or sodium dodecyl sulfate (SDS). In an embodiment, the mild surfactant is or surfactant, or an alkyl ether-PEG surfactant such as PEG (18) tridecyl ether.
[0111] The pKa of TEA is about 7.7, and the pH of the composition can be maintained at about 7.0 to about 8.0 (this is the typical desired pH range for bioassays). In addition, relative to unbound ECL labels as described herein, TEA compositions having a pH of about 7.0 to about 8.0 preferably produce ECL signals from electrode-bound ECL labels. Therefore, compositions comprising TEA herein have the additional advantages of being compatible with the pH of bioassays and not requiring additional pH buffer components, thereby simplifying the production process and reducing the cost of the composition. In an embodiment, the composition comprising TEA is substantially free of additional pH buffer components. Materials that can serve as pH buffer components to maintain a solution within a specific pH range are known to those skilled in the art. For example, buffers capable of maintaining a pH of about 7.0 to about 8.0 include, but are not limited to, piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), choline chloride, 3-(N-morpholino)propanesulfonic acid (MOPS), N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid (TES), 3-(N,N-bis[2-hydroxyethyl]amino)-2-hydroxypropanesulfonic acid (DIPSO), 4-(N-morpholino)butanesulfonic acid (MOBS), acetylaminoglycine, ...
[0014] Examples of pH buffer components include tris(hydroxymethyl)aminomethane ("Tris"), phosphate, HEPES, glycylglycine ("GlyGly"), borate, acetate, and citrate. In an embodiment, the composition comprising TEA does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, and citrate. In embodiments, the composition comprising TEA is substantially free of additional components having a pKa of about 7.0 to about 8.0.
[0112] In addition, many common pH buffer components have tertiary amines in their structures and are capable of producing ECL. Exemplary pH buffer components that can act as ECL co-reactants are provided in US 6,919,173 and include, but are not limited to, HEPES, POPSO, HEPPSO, and PIPES. In an embodiment, the composition comprising TEA is substantially free of additional ECL co-reactants. In an embodiment, the composition comprising TEA does not include any of HEPES, POPSO, HEPPSO, and PIPES. In an embodiment, the composition comprising TEA does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES.
[0113] In embodiments, the concentration of TEA in the composition is about 500 mM to about 7000 mM, about 800 mM to about 6800 mM, about 1000 mM to about 6500 mM, about 1000 mM to about 6400 mM, about 1000 mM to about 6000 mM, about 1000 mM to about 5500 mM, about 1100 mM to about 5000 mM, about 1100 mM to about 4800 mM, about 1100 mM to about 4000 mM, about 1100 mM to about 3500 mM, about 1100 mM to about 3200 mM, about 1100 mM to about 3000 mM, about 1100 mM to about 2500 mM, about 1200 mM to about 2400 mM, or about 1200 mM to about 1600 mM. In embodiments, the concentration of TEA in the composition is about 1000 mM, about 1100 mM, about 1200 mM, about 1300 mM, about 1400 mM, about 1500 mM, about 1600 mM, about 1700 mM, about 1800 mM, about 1900 mM, about 2000 mM, about 2100 mM, about 2200 mM, about 2300 mM, about 2400 mM, about 2500 mM, about 2600 mM, about 2700 mM, about 2800 mM, about 2900 mM, about 3000 mM, about 3100 mM, about 3200 mM, about 3300 mM, about 3400 mM, about 3500 mM, about 3600 mM, about 3700 mM, about 3800 mM, about 3900 mM, about 4000 mM, about 4100 mM, about 4200 mM, about 4300 mM, about 4400 mM, about 4500 mM, about 4600 mM, about 4700 mM, about 4800 mM, about 4900 mM, about 5000 mM, about 5100 mM, about 5200 mM, about 5300 mM, about 5400 mM, about 5500 mM, about 5600 mM, about 5700 mM, about 5800 mM, about 5900 mM, about 6100 mM, about 6200 mM, about 6300 mM, about 6400 mM, about 6500 mM, about 66 00mM, about 4000mM, about 4100mM, about 4200mM, about 4300mM, about 4400mM, about 4500mM, about 4600mM, about 4700mM, about 4800mM, about 4900mM, about 5000mM, about 5100mM, about 5200mM, about 5300mM, about 5400mM, about 5500mM, about 5600mM, about 5700mM, about 5800mM, about 5900mM, about 6000mM, about 6100mM, about 6200mM, about 6300mM, about 6400mM, about 6500mM, about 6600mM, about 6700mM, about 6800mM, about 6900mM or about 7000mM. In embodiments, the concentration of TEA in the composition is at least about 1000 mM, at least about 1200 mM, at least about 1600 mM, at least about 1800 mM, at least about 2000 mM, at least about 2500 mM, at least about 3000 mM, at least about 3500 mM, at least about 4000 mM, at least about 4500 mM, at least about 5000 mM, at least about 5500 mM or at least about 6000 mM.Surprisingly, the concentration of TEA in the composition showed a positive correlation with the intensity of the ECL signal generated, which was unexpected because other ECL co-reactants such as PIPES (which would be expected to behave similarly to TEA since both PIPES and TEA have the ability to confine ECL near the electrode as described herein) have shown a decrease in ECL production with increasing concentration of the ECL co-reactant (see, e.g., . Figure 3A and 3B ). Therefore, the TEA compositions provided herein can preferentially and consistently produce ECL signals from electrode-bound ECL labels relative to unbound ECL labels described herein over a wide concentration range (e.g., from about 1000mM to about 6500mM). In the assay based on ECL, for example, in a washed or unwashed assay format, the consistency of electrode-bound ECL production reduces the variability in ECL production. The ECL co-reactants (e.g., TEA) that can be used in high concentrations provide advantages in non-wash assays by minimizing the dilution of the sample and / or assay mixture, avoiding the disturbance of the binding equilibrium and kinetics of the assay components, and therefore maximizing the ECL signal. The ECL co-reactants (e.g., TEA) that can be used in high concentrations can also be used in assays with lower affinity binding and / or detection reagents, thereby providing improved sensitivity compared to the ECL co-reactants (e.g., PIPES) that can not be used in high concentrations.
[0114] Alkyldiethanolamine / zwitterionic tertiary amine ECL co-reactants
[0115] The present disclosure further provides compositions comprising an alkyldiethanolamine ECL coreactant and / or a zwitterionic tertiary amine ECL coreactant. In embodiments, the alkyldiethanolamine is butyldiethanolamine (BDEA), propyldiethanolamine (PDEA), ethyldiethanolamine (EDEA), methyldiethanolamine (MDEA), or tert-butyldiethanolamine (tBDEA). In embodiments, the alkyldiethanolamine is N-tert-butyldiethanolamine (tBDEA) or methyldiethanolamine (MDEA). In embodiments, the zwitterionic tertiary amine ECL coreactant is dibutylamine propyl sulfonate (DBA-PS), dibutylamine butyl sulfonate (DBA-BS), butylethanolamine propyl sulfonate (BEA-PS), butylethanolamine butyl sulfonate (BEA-BS), diethanolamine propyl sulfonate (also known as 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid; DEA-PS), or diethanolamine butyl sulfonate (DEA-BS). In an embodiment, the zwitterionic tertiary amine ECL co-reactant is DEA-PS. It was found that tBDEA, MDEA, and DEA-PS advantageously exhibit consistent ECL generation properties when used in the absence of a surfactant or when used in combination with different types of surfactants (e.g., the irritating surfactants and mild surfactants described herein). In an embodiment, a composition comprising tBDEA, MDEA, and / or DEA-PS and an irritating surfactant produces an ECL signal substantially similar to a composition comprising the same components when subjected to the same ECL generation conditions (e.g., voltage waveform, electrode type, amount of composition, amount of ECL label, etc.), except that a mild surfactant is present instead of an irritating surfactant. In an embodiment, the irritating surfactant is TRITON TM X-100, TRITON TM X-114, NP-40, CA-630, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS) or sodium dodecyl sulfate (SDS). In an embodiment, the mild surfactant is or surfactant, or an alkyl ether-PEG surfactant such as PEG (18) tridecyl ether.
[0116] In embodiments, the concentration of the alkyldiethanolamine or zwitterionic tertiary amine in the composition is about 10 mM to about 500 mM, about 20 mM to about 400 mM, about 50 mM to about 250 mM, or about 100 mM to about 200 mM. In embodiments, the concentration of the alkyldiethanolamine, zwitterionic tertiary amine, in the composition is about 10 mM, about 20 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In embodiments, the alkyldiethanolamine is tBDEA. In embodiments, the alkyldiethanolamine is MDEA. In embodiments, the alkyldiethanolamine is a combination of tBDEA and MDEA. In embodiments, the zwitterionic tertiary amine is DEA-PS. In embodiments, the composition includes a combination of two or more of tBDEA, MDEA, and DEA-PS.
[0117] In an embodiment, the composition comprising alkyldiethanolamine and / or zwitterionic tertiary amine (e.g., tBDEA, MDEA and / or DEA-PS) further comprises a pH buffer component. In an embodiment, the pKa of the pH buffer component is from about 7.0 to about 8.0. In an embodiment, the pH buffer component is capable of maintaining the pH of the composition at from about 7.0 to about 8.5, from about 7.2 to about 8.0, or from about 7.4 to about 7.9. In an embodiment, the pH buffer component comprises Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, PIPES, MOPS, TES, DIPSO, MOBS, TAPSO, POPSO, HEPPSO, HEPPS, tricine, glycine amide, HEPBS, bicine, or a combination thereof. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the pH buffer component comprises Tris. In an embodiment, the pH buffer component comprises phosphate.
[0118] In embodiments, the concentration of the pH buffer component in the composition is about 10 mM to about 800 mM, about 20 mM to about 600 mM, about 50 mM to about 400 mM, about 100 mM to about 300 mM, about 120 mM to about 280 mM, or about 150 mM to about 250 mM. In embodiments, the concentration of the pH buffer component in the composition is about 50 mM, about 100 mM, about 150 mM, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM.
[0119] Ionic components
[0120] In an embodiment, the composition of the present invention includes an ionic component. Ionic components such as salts dissociate into ions in solution. It has been found that high ionic concentrations can advantageously reduce nonspecific binding of ECL labels to ECL co-reactants. Non-limiting examples of ionic components include cationic Li + 、Na + , K + , Rb + 、Cs + Mg +2 , Ca +2 and NH4 + and / or comprising an anion F - 、Cl - Br - , I - , phosphates, sulfates and borates. In an embodiment, the ionic components include Li + 、Na + or K + In an embodiment, the ionic components include Cl - In an embodiment, the ionic component comprises lithium chloride (LiCl), sodium chloride (NaCl), potassium chloride (KCl), or a combination thereof. In an embodiment, the ionic component comprises NaCl. In an embodiment, the ionic component comprises KCl.
[0121] In embodiments, the concentration of the ionic component in the composition is about 100 mM to about 2000 mM, about 200 mM to about 1800 mM, about 300 mM to about 1700 mM, about 400 mM to about 1600 mM, about 500 mM to about 1500 mM, about 600 mM to about 1200 mM, about 700 mM to about 1000 mM, or about 800 mM to about 900 mM. In embodiments, the concentration of the ionic component in the composition is about 500 mM, about 550 mM, about 600 mM, about 650 mM, about 700 mM, about 750 mM, about 800 mM, about 850 mM, about 900 mM, about 950 mM, about 1000 mM, about 1100 mM, about 1200 mM, about 1300 mM, about 1400 mM or about 1500 mM.
[0122] In an embodiment, the composition comprises about 100mM to about 2000mM, about 200mM to about 1800mM, about 300mM to about 1700mM, about 400mM to about 1600mM, about 500mM to about 1500mM, about 600mM to about 1200mM, about 700mM to about 1000mM, or about 800mM to about 900mM NaCl. In an embodiment, the composition comprises about 100mM to about 2000mM, about 200mM to about 1800mM, about 300mM to about 1700mM, about 400mM to about 1600mM, about 500mM to about 1500mM, about 600mM to about 1200mM, about 700mM to about 1000mM, or about 800mM to about 900mM KCl. In embodiments, the composition comprises about 100 mM to about 2000 mM, about 200 mM to about 1800 mM, about 300 mM to about 1700 mM, about 400 mM to about 1600 mM, about 500 mM to about 1500 mM, about 600 mM to about 1200 mM, about 700 mM to about 1000 mM, or about 800 mM to about 900 mM LiCl.
[0123] In embodiments, the ionic strength of the composition is from about 0.2 M to about 2 M, from about 0.5 M to about 1.5 M, from about 0.75 M to about 1.25 M, or from about 0.8 M to about 1.0 M. In embodiments, the ionic strength of the composition is greater than or about 0.3 M, greater than or about 0.5 M, greater than or about 0.8 M, or greater than or about 1.0 M. In embodiments, the composition includes chloride ions, and the concentration of chloride ions is greater than or about 0.3 M, greater than or about 0.5 M, greater than or about 0.8 M, or greater than or about 1.0 M.
[0124] In embodiments, a composition comprising an ionic component has lower non-specific binding (NSB) in an immunoassay with ECL as the assay readout compared to an otherwise identical composition without the ionic component.
[0125] surfactants
[0126] It has been unexpectedly discovered that when using the compositions provided herein (e.g., compositions comprising TEA, tBDEA, MDEA, and / or DEA-PS) as ECL co-reactants, the ECL generation properties of the compositions are substantially unaffected by the presence, concentration, or structure of surfactants in the compositions. In contrast, TPA-based compositions generally require the presence of surfactants to produce an optimal signal. Specifically, in the presence of surfactants comprising an aromatic moiety (e.g., TRITON TM In the case of the phenol ether moiety in X-100, TPA provided the best ECL generation.
[0127] In an embodiment, the composition herein is substantially free of surfactant. In an embodiment, the composition herein includes a surfactant. In an embodiment, the composition herein includes a surfactant having a concentration lower than the critical micelle concentration (CMC) of the surfactant. CMC is the concentration of the surfactant that forms micelles on the surfactant, and any additional amount of surfactant added to the composition exceeding CMC is incorporated into the micelle. The CMC of the surfactant can be determined by those skilled in the art, for example, using a titration method as described in Wu et al., "Analytical Chemistry (Anal Chem)" 92 (6): 4259-4265 (2020), and / or using devices such as dynamic contact angle measuring devices and / or tensiometers.
[0128] In embodiments, the compositions herein include a nonionic surfactant. In embodiments, the compositions herein include an ionic surfactant. Nonionic surfactants include the class of surfactants known under the trade names: NONIDET TM (octylphenoxypolyethoxyethanol), (polyoxyethylene fatty ether), TRITON TM (2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol), (polysorbate), (polyoxyl castor oil), (polyethylene glycol lauryl ether), (polyoxyethylene alkyl ether), (isotridecyl alcohol polyglycol ether), (poloxamer block copolymer of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO)) (arranged as PEO-PPO-PEO), (Poloxamine block copolymer of PEO-PPO), (block copolymer of poly(ethylene glycol) (PEG) and poly(propylene glycol) (PPG)) (arranged as PEG-PPG-PEG) and (sorbitan). Specific examples of nonionic surfactants include, for example, P-407(PEG 101 -PPG 56 -PEG 101 ; also known as Poloxamer 407), P-123(PEO 18 -PPO 72 -PEO 18 ), L-121(PEG5-PPG 68 -PEG5), 31R1(PPO 26 -PEO5-PPO 26 ), 701 (ethylenediaminetetrakis(propoxylate-block-ethoxylate)tetraol), L4 (polyethylene glycol lauryl ether), 58 (polyethylene glycol cetyl ether), 20 (polysorbate 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate and alkyl ether-polyethylene glycol (PEG), such as PEG (10) tridecyl ether, PEG (12) tridecyl ether and PEG (18) tridecyl ether.
[0129] In an embodiment, the surfactant comprises a phenol ether. In an embodiment, the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100). In the context of the surfactants described herein, TRITON TM X-100 is a "harsh" surfactant that is capable of disrupting, lysing and / or solubilizing lipid bilayer membranes, such as cell membranes or extracellular vesicles (EVs).
[0130] In embodiments, the surfactant does not include an aromatic moiety. In embodiments, the surfactant does not include a phenolic ether. In embodiments, the surfactant does not disrupt, lyse, or dissolve lipid bilayer membranes, e.g., cell membranes or extracellular vesicles (EVs). Such surfactants may be referred to as "mild" surfactants. Examples of mild surfactants include those sold under the trade names or In an embodiment, the surfactant does not include an ester bond. In an embodiment, the surfactant is Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the surfactant is an alkyl ether-polyethylene glycol (PEG). In an embodiment, the alkyl ether-polyethylene glycol (PEG) is PEG (10) tridecyl ether, PEG (12) tridecyl ether, PEG (18) tridecyl ether, or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether.
[0131] As described herein, the compositions herein advantageously provide consistent ECL signal generation in the presence of different types of surfactants (e.g., irritating surfactants and mild surfactants described herein). In embodiments, when subjected to the same conditions for generating ECL (e.g., voltage waveform, electrode type, amount of composition, amount of ECL label, etc.), except for the presence of a mild surfactant instead of an irritating surfactant, a composition comprising TEA, tBDEA, MDEA, DEA-PS, or a combination thereof, and an irritating surfactant produces an ECL signal substantially similar to a composition comprising the same components. In embodiments, when subjected to the same conditions for generating ECL (e.g., voltage waveform, electrode type, amount of composition, amount of ECL label, etc.), except for the presence of a mild surfactant instead of an irritating surfactant, a composition comprising TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof, and an irritating surfactant produces an ECL signal substantially similar to a composition comprising the same components. In embodiments, the irritating surfactant is TRITON TM X-100. In an embodiment, the mild surfactant is or surfactant, or an alkyl ether-PEG surfactant such as PEG (18) tridecyl ether.
[0132] In embodiments, the concentration of the surfactant in the composition is such that the air-liquid surface tension of the composition is less than or about 50 dynes / cm, less than or about 40 dynes / cm, or less than or about 35 dynes / cm. In embodiments, the surfactant is present in the composition at its cmc, at greater than or about twice its cmc, or at greater than or about five times its cmc.
[0133] In embodiments, the surfactant is about 0.1% (v), about 0.5% (v / v), about 1% (v / v), about 2% (v / v), about 5% (v / v), about 7% (v / v), or about 10% (v / v) of the composition. In embodiments, the concentration of the surfactant in the composition is about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM. In embodiments, the concentration of the surfactant in the composition is about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM or about 10 mM.
[0134] In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM poloxamer 407 ( P-407). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM PEO 18 -PPO 72 -PEO 18 ( P-123). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM PEG5-PPG 68 -PEG5( L-121). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM PPO 26 -PEO5-PPO 26 ( 31R1). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM ethylenediaminetetrakis(propoxylate-block-ethoxylate)tetraol ( 701). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM polyethylene glycol lauryl ether ( L4). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM polyethylene glycol hexadecyl ether ( 58). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM polysorbate 20 ( 20). In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate. In embodiments, the composition comprises about 0.1 mM to about 20 mM, about 0.1 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.75 mM to about 6 mM, or about 1 mM to about 5 mM alkyl ether-PEG. In embodiments, the alkyl ether-PEG is PEG (18) tridecyl ether.
[0135] pH
[0136] In embodiments, the compositions herein have a pH of about 6.0 to about 9.0, a pH of about 7.0 to about 8.0, a pH of about 7.2 to about 7.6, a pH of about 7.5 to about 7.8, a pH of about 7.4 to about 7.9, a pH of about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, or about 8.0. In embodiments, the compositions have a pH of about 7.5. In embodiments, the compositions have a pH of about 7.8.
[0137] In an embodiment, the pH of the composition comprising TEA is about 7.0 to about 8.0, about 7.4 to about 7.9, or about 7.5 to about 7.8, and is substantially free of additional pH buffer components. In an embodiment, the pH of the composition comprising TEA is about 7.0 to about 8.0, about 7.4 to about 7.9, or about 7.5 to about 7.8, and is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition comprising TEA does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, and citrate. In an embodiment, the composition comprising TEA does not include any of HEPES, POPSO, HEPPSO, and PIPES. In an embodiment, the composition comprising TEA does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES.
[0138] ECL-labeled components
[0139] In an embodiment, the composition herein includes an ECL-labeled component. In an embodiment, the ECL co-reactant composition provided herein (e.g., an ECL co-reactant composition including TEA, tBDEA, MDEA and / or DEA-PS and an ECL-labeled component) is capable of producing ECL. In an embodiment, the ECL-labeled component includes an ECL label. In an embodiment, the ECL-labeled component includes a detection reagent. In an embodiment, the ECL-labeled component includes a binding partner for a detection reagent.
[0140] In an embodiment, the component of the ECL label is a detection reagent comprising an ECL label. In an embodiment, the detection reagent comprises an antibody or its antigen detection fragment, an antigen, a ligand, a receptor, an oligonucleotide, a hapten, an epitope, a mimotope or an aptamer. In an embodiment, the detection reagent is an antibody or a variant thereof, comprising its antigen / epitope detection portion, an antibody fragment or derivative, an antibody analog, an engineered antibody or a substance that binds to an antigen in a manner similar to an antibody. In an embodiment, the detection reagent comprises at least one heavy chain or light chain complementary determining region (CDR) of an antibody. In an embodiment, the detection reagent comprises at least two CDRs from one or more antibodies. In an embodiment, the detection reagent is an antibody or its antigen detection fragment. In an embodiment, the detection reagent is covalently linked to the ECL label via a conjugated linker. The method of conjugating a label (e.g., an ECL label) to a detection reagent is known to those of ordinary skill in the art.
[0141] In an embodiment, the ECL-labeled component is a binding partner of a detection reagent. In an embodiment, the ECL-labeled component and the detection reagent form a complex that can be detected by ECL. In an embodiment, the ECL-labeled component and the detection reagent include a receptor-ligand pair, an antigen-antibody pair, a hapten-antibody pair, an epitope-antibody pair, a mimotope-antibody pair, an aptamer-target molecule pair, or an intercalator-target molecule pair. In an embodiment, the ECL-labeled component and the detection reagent include complementary oligonucleotides. In an embodiment, the ECL-labeled component and the detection reagent include a biotin-avidin or biotin-streptavidin pair.
[0142] In an embodiment, the component of the ECL labeling is an oligonucleotide. In an embodiment, the ECL labeling oligonucleotide and the detection reagent comprise complementary oligonucleotides, and in other embodiments, the ECL labeling oligonucleotide is a detection reagent. In an embodiment, the binding reagent comprises an oligonucleotide, and the ECL labeling oligonucleotide is complementary to the oligonucleotide. In an embodiment, the binding partner comprises an oligonucleotide, and the ECL labeling oligonucleotide is complementary to the binding partner oligonucleotide. In an embodiment, the binding partner is an analyte oligonucleotide, and the ECL labeling oligonucleotide is complementary to the analyte oligonucleotide. In an embodiment, the binding partner of the ECL labeling oligonucleotide is an analyte oligonucleotide, the ECL labeling oligonucleotide is complementary to a part of the analyte oligonucleotide, and the binding reagent is a capture oligonucleotide complementary to different parts of the analyte oligonucleotide. In an embodiment, the component of the ECL labeling is an oligonucleotide probe complementary to an extension primer, and the extension primer is connected to a detection reagent (e.g., a detection antibody) bound to a target analyte (such as a peptide or protein). In embodiments, the binding agent is streptavidin and the binding complex comprising the oligonucleotide is a complex of a biotinylated capture antibody, a peptide, and a secondary antibody comprising an oligonucleotide primer (see, for example, but not limited to, Figure 20 ).
[0143] In an embodiment, the ECL-labeled oligonucleotide is a probe. In an embodiment, the ECL-labeled oligonucleotide is a probe that is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 or more nucleotides long, or a range defined by any two of the foregoing values. In one embodiment, the ECL-labeled oligonucleotide probe comprises a stem-loop or hairpin structure, an ECL label, and a quenching moiety, wherein the quenching moiety is proximal to the ECL label and quenches the ECL label when the ECL-labeled oligonucleotide probe is in the stem-loop or hairpin configuration, but does not quench the ECL label when the stem-loop or hairpin structure is in an open configuration. In an embodiment, the ECL-labeled oligonucleotide probe having a stem-loop or hairpin structure is an ECL-labeled molecular beacon probe. In an embodiment, the binding partner of the ECL-labeled hairpin or molecular beacon oligonucleotide probe is an analyte oligonucleotide, the ECL-labeled oligonucleotide probe is complementary to a portion of the analyte oligonucleotide, and the binding reagent is a capture oligonucleotide complementary to a different portion of the analyte oligonucleotide (see, for example, but not limited to, Figure 14 In an embodiment, the ECL-labeled molecular beacon probe is complementary to an extension primer, which is linked to a detection reagent (e.g., a detection antibody) that binds to a target analyte (e.g., a peptide or protein) (see, for example, but not limited to, Figure 20 ).
[0144] ECL labeled molecular beacon probes can be prepared using conventional methods known in the art for conventional molecular beacon probes. In an embodiment, the probe can have a probe sequence of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 bases in length, or a range defined by any two of the foregoing values, such as a probe sequence of 10 to 30, 10 to 15, or 15 to 30 bases and a 5' and 3' stem complement sequence of 5, 6, 7, 8, 9, 10, 11, 12, 13 bases in length, or a range defined by any two of the foregoing values, such as a 5' and 3' stem complement sequence of 5 to 8 bases. In an embodiment, the stem is 5-8 base pairs long and has a very high GC content (75% to 100%). In an embodiment, the molecular beacon probe of ECL labeling is labeled at 5' and 3' ends, with ECL labeling and quenching moiety, such as 5' ECL labeling or 3' quenching moiety, and vice versa. The design tool of conventional molecular beacon probe can be found at www.molecular-beacons.org / MB_SC_design. In an embodiment, the use of short probe sequence can reduce the need for the use of stem-loop structure, thereby allowing more effective static quenching by contact. In order to achieve these goals, molecular beacons based on LNA sequences have been shown to be valuable. Examples can be found in Eboigbodin KE et al., Rapid and sensitive real-time assay for the detection of respiratory syncytial virus using RT-SIBA, BMC Infect Dis. 2017, which is incorporated herein by reference in its entirety. An example of such a probe is / 56-ROXN / +CA+A+TA+T+T+GA+GA+TA / 3IABkFQ / . In an embodiment, the ECL-labeled oligonucleotide probe can be prepared using duplex stabilization technology (Minor Groove Binder, MGB TM ), The probes were designed by Biosearch Technology to allow for shorter probe design. Minor groove binders are available as phosphoramidites and CPG, allowing them to be included in the oligonucleotide synthesis process during probe synthesis (IDT). One example is to use an MGB-CPG support, add a quencher molecule, followed by the sequence and a final 5' amino group for labeling with an ECL moiety. Alternatively, it can be added post-synthesis by using NHS ester-based labeling of the amino group introduced during oligonucleotide synthesis. Minor groove binders include those described in US-9,334,495, which is incorporated herein by reference in its entirety.
[0145] In embodiments, an ECL-labeled oligonucleotide probe comprises an ECL label and a quencher, wherein the ECL label and the quencher are sufficiently close to each other on the probe when the probe is in a linear configuration (e.g., not in a stem-loop or hairpin configuration) such that the quencher quenches the ECL signal regardless of whether the probe is hybridized to a complementary oligonucleotide (e.g., as in Figure 21 Such ECL-labeled probes can be prepared using conventional methods known in the art, such as for designing In an embodiment, the ECL-labeled oligonucleotide probe is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 or more nucleotides long, or a range defined by any two of the aforementioned values. In an embodiment, the ECL-labeled probe is labeled at the 5' and 3' ends, with an ECL label and a quencher moiety, such as a 5' ECL label or a 3' quencher moiety, or vice versa. In an embodiment, one or both of the ECL label and the quencher moiety are connected at a position other than the 5' or 3' end of the oligonucleotide. In an embodiment, the quencher moiety is located at the 5' end of the oligonucleotide.
[0146] In an embodiment, the ECL-labeled oligonucleotide probe is DNA, RNA, a mixture of the two and / or includes one or more modified nucleic acids. In an embodiment, the ECL-labeled oligonucleotide includes one or more nucleotides that are resistant to enzymatic cleavage, for example, by exonucleases or endonucleases. In an embodiment, the resistant nucleotide is a peptide nucleic acid or other resistant nucleic acid mimics known in the art. In an embodiment, only a portion of the ECL-labeled oligonucleotide probe is resistant, and the quenching portion is on a portion that is not resistant (e.g., the 5' portion), while the ECL label is on a portion that is resistant (e.g., the center and / or 3' portion), so that when the enzyme (e.g., 5' exonuclease) cuts the ECL-labeled oligonucleotide, the quenching portion is released into the solution, and the resistant portion of the ECL-labeled probe including the ECL label remains hybridized with a complementary oligonucleotide (e.g., an oligonucleotide that binds to a partner and / or a binding complex). In embodiments, the ECL-labeled oligonucleotide probe includes, for example, but not limited to, features of a sequence and / or type (e.g., RNA) of nucleotides that are recognized by an enzyme that cleaves the ECL-labeled oligonucleotide probe only when the ECL-labeled oligonucleotide probe is hybridized to a complementary oligonucleotide (e.g., a binding partner and / or an oligonucleotide of a binding complex) (e.g., as in Figure 21 ). In embodiments, the enzyme is a restriction endonuclease, optionally a nicking endonuclease, and the feature is a sequence recognized by the restriction endonuclease, or the enzyme is a RNasH2 enzyme, and the feature is one or more RNA nucleotides. In embodiments, the ECL-labeled oligonucleotide probe comprises a feature proximal to a quenching moiety such that when the enzyme cleaves the ECL-labeled oligonucleotide probe, the quenching moiety is released into solution, and the ECL-labeled probe comprising the ECL label remains hybridized to a complementary oligonucleotide (e.g., an oligonucleotide binding partner and / or binding complex).
[0147] In an embodiment, a plurality of ECL-labeled oligonucleotide probes can be used. In an embodiment, a plurality of ECL-labeled oligonucleotide probes each having a different sequence complementary to a sequence of a different target oligonucleotide (e.g., an oligonucleotide on a binding reagent, a detection reagent, a binding partner and / or an oligonucleotide analyte) allow the ECL-labeled oligonucleotide probe to specifically hybridize with its corresponding target oligonucleotide. In certain embodiments, the target oligonucleotide is positioned at a known position on the substrate so that the presence of an ECL signal at a known position can be related to the presence of the target oligonucleotide (e.g., an oligonucleotide on a binding reagent, a detection reagent, a binding partner and / or an oligonucleotide analyte). In certain embodiments, a plurality of different target oligonucleotides are positioned at a plurality of points on the bottom surface of a culture plate well, wherein each target oligonucleotide with a specific sequence is positioned to a specific predetermined point. In certain embodiments, each point contains a specific, fixed binding reagent (e.g., a capture oligonucleotide) that is different from the binding reagent of other points (e.g., the bottom of the plate well) fixed to the substrate surface. Each point can be coated with an electrode layer, and the binding reagent is fixed on the electrode layer. In this way, a plurality of ECL-labeled oligonucleotide probes can be used to perform a multiple reaction. In certain embodiments, the multiplex reaction utilizes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more different ECL-labeled oligonucleotide probes, each ECL-labeled oligonucleotide probe having a different oligonucleotide sequence complementary to a different target oligonucleotide. In an embodiment, the ECL label is a label described in the following paragraphs herein. In an embodiment, the quencher moiety is selected from the group consisting of: ATTO 540Q, ATTO 575Q, ATTO 580Q, ATTO 612Q, Iowa Black FQ, Iowa Back RQ, QSY21, IRDye QC-1, BHQ0, BHQ1, BHQ-2, BHQ-3, Dabcyl, QSY 7, QSY 9, QSY 21, QSY 35, QXL 490, QXL 520, QXL 570, and QXL 670. In an embodiment, the quencher moiety is an anti-ECL label antibody or a binding fragment thereof. In an embodiment, the quencher moiety is ferrocene or iron tris-bipyridine. In an embodiment, the ECL label has the following formula II. In an embodiment, the ECL label has the following formula II and the quencher moiety is BHQ2. In an embodiment, the ECL label has the following formula II and the quencher moiety is Iowa Black. In an embodiment, the ECL label has the following formula II and the quencher moiety is Dabcyl.
[0148] In an embodiment, the ECL label comprises an electrochemiluminescent organometallic complex. In an embodiment, the electrochemiluminescent organometallic complex comprises ruthenium, osmium, iridium, rhenium and / or a lanthanide metal. In an embodiment, the ECL label comprises ruthenium. In an embodiment, the electrochemiluminescent organometallic complex comprises a substituted or unsubstituted bipyridine or a substituted or unsubstituted phenanthroline. In an embodiment, the ECL label comprises a substituted bipyridine. In an embodiment, the ECL label comprises ruthenium(II) tris-bipyridine. In an embodiment, the ECL label comprises an organometallic complex comprising at least one substituted bipyridine ligand, wherein the substituted bipyridine ligand comprises at least one sulfonate group. In an embodiment, the ECL label comprises an organometallic complex comprising at least two substituted bipyridine ligands, wherein each substituted bipyridine ligand comprises at least one sulfonate group. In an embodiment, the substituted bipyridine ligand comprising at least one sulfonate group is a compound of Formula I:
[0149]
[0150] In an embodiment, the ECL label comprises three ligands, wherein the first ligand is a compound of Formula I, and wherein the second ligand comprises a bipyridine having at least one substituent covalently attached to a detection agent. In an embodiment, the ECL label comprises an organometallic complex comprising three ligands, wherein two of the ligands are each a compound of Formula I, and wherein the third ligand comprises a bipyridine having at least one substituent covalently attached to a detection agent.
[0151] In embodiments, the first detectable label comprises a compound of Formula II:
[0152]
[0153] Additional exemplary ECL labels can be found in US 5,714,089; US 6,136,268; US 6,316,607; US 6,468,741; US 6,479,233; US 6,808,939; and US 9,499,573, each of which is herein incorporated by reference in its entirety.
[0154] TEA composition
[0155] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA and about 500 mM to about 1500 mM ionic component, wherein the pH of the composition is about 7.0 to about 8.0; and wherein the ionic component is NaCl, KCl or LiCl. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0156] In an embodiment, the present disclosure provides a composition comprising about 1100 mM to about 3500 mM TEA and about 600 mM to about 1200 mM ionic component, wherein the pH of the composition is about 7.0 to about 8.0; and wherein the ionic component is NaCl, KCl or LiCl. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0157] In an embodiment, the present disclosure provides a composition comprising about 1200 mM to about 1600 mM TEA and about 700 mM to about 900 mM ionic component, wherein the pH of the composition is about 7.0 to about 8.0; and wherein the ionic component is NaCl, KCl, or LiCl. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label. In an embodiment, the composition comprises about 1200 mM TEA and about 850 mM NaCl. In an embodiment, the composition comprises about 1600 mM TEA and about 850 mM NaCl. In an embodiment, the composition comprises about 1200mM TEA and about 850mM KCl. In an embodiment, the composition comprises about 1600mM TEA and about 850mM KCl. In an embodiment, the composition comprises about 1200mM TEA and about 850mM LiCl. In an embodiment, the composition comprises about 1600mM TEA and about 850mM LiCl. In an embodiment, the pH of the composition is about 7.5. In an embodiment, the pH of the composition is about 7.8.
[0158] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 500 mM to about 1500 mM ionic component, and about 0.1 mM to about 10 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0159] In an embodiment, the present disclosure provides a composition comprising about 1100 mM to about 3500 mM TEA, about 600 mM to about 1200 mM ionic component, and about 0.5 mM to about 8 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0160] In an embodiment, the present disclosure provides a composition comprising about 1200 mM to about 1600 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.4 to about 7.9; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0161] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.4 to about 7.9; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0162] In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.4 to about 7.9; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0163] In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.4 to about 7.9; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0164] In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.4 to about 7.9; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0165] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0166] In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0167] In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0168] In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0169] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 850 mM NaCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0170] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 850 mM KCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0171] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 850 mM LiCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0172] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100). In embodiments, the composition is substantially free of additional pH buffering components. In embodiments, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In embodiments, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In embodiments, the composition further includes an ECL-labeled component. In embodiments, the ECL-labeled component is a detection reagent comprising an ECL label.
[0173] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0174] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0175] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.5; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0176] In an embodiment, the present disclosure provides a composition comprising about 1000 mM to about 6500 mM TEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.8; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0177] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0178] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0179] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0180] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM NaCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM NaCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0181] In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM NaCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM NaCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0182] In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM NaCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM NaCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0183] In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM NaCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM NaCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0184] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM KCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM KCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0185] In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM KCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM KCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0186] In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM KCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM KCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0187] In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM KCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM KCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0188] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM LiCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM LiCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0189] In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM LiCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM LiCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0190] In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM LiCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM LiCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0191] In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM LiCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM LiCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the composition is substantially free of additional pH buffer components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0192] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0193] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0194] In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1200 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 1600 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 3200 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 6400 mM TEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition is substantially free of additional components having a pKa of about 7.0 to about 8.0. In an embodiment, the composition does not include any of Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, POPSO, HEPPSO, and PIPES. In an embodiment, the composition further includes an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent including an ECL label.
[0195] In an embodiment, the present disclosure provides a composition comprising: TEA, an ionic component, and optionally one or both of an ECL-labeled component and a surfactant, wherein the pH of the composition is about 7.0 to about 8.0, and optionally wherein the composition is substantially free of additional pH buffering components. In an embodiment, the composition comprises about 1000 mM to about 6500 mM TEA and about 500 mM to about 2000 mM ionic component. In an embodiment, the surfactant comprises an alkyl ether-PEG. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition consists essentially of or consists of the recited components.
[0196] In an embodiment, the present disclosure provides a composition comprising: one or both of TEA, an ionic component, an ECL-labeled component, and a surfactant, wherein the pH of the composition is about 7.0 to about 8.0, and optionally wherein the composition is substantially free of additional pH buffering components. In an embodiment, the composition comprises about 1000 mM to about 6500 mM TEA and about 500 mM to about 2000 mM ionic components. In an embodiment, the surfactant comprises an alkyl ether-PEG. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition consists essentially of or consists of the recited components.
[0197] In an embodiment, the present disclosure provides a composition comprising: TEA, an ionic component, and optionally one or both of an ECL-labeled component and a surfactant, wherein the pH of the composition is from about 7.0 to about 8.0, and wherein the composition is substantially free of additional pH buffering components. In an embodiment, the composition comprises from about 1000 mM to about 6500 mM TEA and from about 500 mM to about 2000 mM ionic component. In an embodiment, the surfactant comprises an alkyl ether-PEG. In an embodiment, the composition consists essentially of or consists of the recited components.
[0198] In an embodiment, the present disclosure provides a composition comprising: TEA, an ionic component, and an ECL-labeled component; wherein the pH of the composition is about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition comprising: TEA, an ionic component, and a surfactant; wherein the pH of the composition is about 7.0 to about 8.0. In an embodiment, the present disclosure provides a composition comprising: TEA, an ionic component, an ECL-labeled component, and a surfactant; wherein the pH of the composition is about 7.0 to about 8.0. In an embodiment, the composition comprises about 1000 mM to about 6500 mM TEA and about 500 mM to about 2000 mM ionic component. In an embodiment, the surfactant comprises alkyl ether-PEG. In an embodiment, the composition is substantially free of additional pH buffering components. In an embodiment, the composition consists essentially of or consists of the recited components.
[0199] In an embodiment, the composition provided herein is in a dry form. In an embodiment, the composition provided herein is in a dry powder form. In an embodiment, the composition provided herein is a lyophilized powder. Throughout this disclosure, when a composition includes a certain concentration of its described components (e.g., about 1000mM to about 6500mM TEA; about 500mM to about 2000mM ionic components; and / or about 0.1mM to about 10mM surfactant) and / or a certain pH of its described components (e.g., pH is about 7.0 to about 8.0), it will be understood by those of ordinary skill in the art that the described concentration of the components and the pH of the composition refer to a composition in liquid form, for example, a dry composition reconstituted with a liquid diluent (e.g., water or aqueous assay buffer). In an embodiment, the composition is in a dry form and includes the described components at the described concentration when reconstituted with a liquid diluent. In an embodiment, the composition is in a dry form and includes the described pH when constituted with a liquid diluent.
[0200] Alkyldiethanolamine / zwitterionic tertiary amine composition
[0201] In an embodiment, the present disclosure provides a composition comprising about 50 mM to about 250 mM tBDEA, about 500 mM to about 1500 mM ionic component, and about 0.1 mM to about 10 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0202] In an embodiment, the present disclosure provides a composition comprising about 50 mM to about 250 mM MDEA, about 500 mM to about 1500 mM ionic component, and about 0.1 mM to about 10 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0203] In an embodiment, the present disclosure provides a composition comprising about 50 mM to about 250 mM DEA-PS, about 500 mM to about 1500 mM ionic component, and about 0.1 mM to about 10 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0204] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0205] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0206] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0207] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0208] In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0209] In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0210] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0211] In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0212] In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0213] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 850 mM NaCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0214] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 850 mM NaCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0215] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 850 mM NaCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0216] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 850 mM KCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0217] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 850 mM KCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0218] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 850 mM KCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0219] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 850 mM LiCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0220] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 850 mM LiCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0221] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 850 mM LiCl, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0222] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100). In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100). In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100). In embodiments, the composition further comprises about 100 mM to about 200 mM pH buffer component. In embodiments, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In embodiments, the composition further comprises an ECL-labeled component. In embodiments, the ECL-labeled component is a detection reagent comprising an ECL label.
[0223] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0224] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is PEG (18) tridecyl ether. In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is PEG (18) tridecyl ether. In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 700 mM to about 900 mM ionic component and about 1 mM surfactant, wherein the pH of the composition is about 7.0 to about 8.0; wherein the ionic component is NaCl, KCl or LiCl, and wherein the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0225] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.5; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0226] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM tBDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.8; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0227] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.5; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0228] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM MDEA, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.8; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0229] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.5; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0230] In an embodiment, the present disclosure provides a composition comprising about 100 mM to about 200 mM DEA-PS, about 700 mM to about 900 mM ionic component, and about 1 mM to about 5 mM surfactant, wherein the pH of the composition is about 7.8; wherein the ionic component is NaCl, KCl, or LiCl; and wherein the surfactant is 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), Poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG) or a combination thereof. In an embodiment, the surfactant is PEG (18) tridecyl ether. In an embodiment, the composition further comprises about 100mM to about 200mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0231] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM NaCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100), wherein the pH of the composition is about 7.8. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0232] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM KCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100), wherein the pH of the composition is about 7.8. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0233] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TM X-100), wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM LiCl, and about 1 mM 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol (TRITON TMX-100), wherein the pH of the composition is about 7.8. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0234] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM NaCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM NaCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0235] In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM NaCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM NaCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0236] In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM NaCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM NaCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0237] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM KCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM KCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72-PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0238] In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM KCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM KCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0239] In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM KCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM KCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0240] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM LiCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM LiCl, and about 1 mM surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0241] In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM LiCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68-PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM LiCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0242] In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM LiCl, and about 1% surfactant, wherein the pH of the composition is about 7.5, and wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM LiCl, and about 1 surfactant, wherein the pH of the composition is about 7.8, wherein the surfactant is poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate, alkyl ether-polyethylene glycol (PEG), or a combination thereof. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycylglycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0243] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM NaCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0244] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM KCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0245] In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM tBDEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM MDEA, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.5. In an embodiment, the present disclosure provides a composition comprising about 150 mM DEA-PS, about 850 mM LiCl, and about 1 mM PEG (18) tridecyl ether, wherein the pH of the composition is about 7.8. In an embodiment, the composition further comprises about 100 mM to about 200 mM pH buffer component. In an embodiment, the pH buffer component is Tris, phosphate, HEPES, glycine, borate, acetate, citrate, or a combination thereof. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0246] In an embodiment, the present disclosure provides a composition comprising an ECL coreactant, an ionic component, and a surfactant. In an embodiment, the ECL coreactant is tributylamine (TBA), (dibutyl)aminoethanol (DBAE), (diethyl)aminoethanol (DEAE), triethanolamine (TEA), butyldiethanolamine (BDEA), propyldiethanolamine (PDEA), ethyldiethanolamine (EDEA), methyldiethanolamine (MDEA), tert-butyldiethanolamine (tBDEA), dibutylamine (DBA), butylethanolamine (BEA), diethanolamine (DEA), dibutylamine propyl sulfonate (DBA-PS), dibutylamine butyl sulfonate (DBA-BS), butylethanolamine propyl sulfonate (BEA-PS), butylethanolamine butyl sulfonate (BEA-BS), diethanolamine propyl sulfonate (also known as 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid; DEA-PS), diethanolamine butyl sulfonate (DEA-BS), or a combination thereof. In an embodiment, the pH of the composition is from about 7.0 to about 8.0. In an embodiment, the composition further comprises a pH buffer component. Provided herein are suitable ionic components (e.g., NaCl, KCl, and LiCl), surfactants (e.g., TRITON X-100 or mild surfactants described herein), pH buffer components (e.g., Tris or phosphate) and their concentrations in the composition. In an embodiment, the composition further comprises an ECL-labeled component. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label.
[0247] method
[0248] In an embodiment, the present disclosure provides a method for generating electrochemiluminescence (ECL), comprising: (a) contacting an electrode with an ECL co-reactant composition provided herein, (b) applying a voltage to the electrode; and (c) generating ECL. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the present disclosure provides a method for generating electrochemiluminescence (ECL), comprising: (a) contacting an electrode with a TEA composition comprising TEA, an ionic component, and optionally a surfactant; (b) applying a voltage to the electrode; and (c) generating ECL. In an embodiment, the method further comprises detecting the generated ECL. In an embodiment, the method further comprises measuring the generated ECL. In an embodiment, the electrode is present on a surface.
[0249] In an embodiment, the present disclosure provides a method for generating electrochemiluminescence (ECL), the method comprising: (a) contacting an electrode with: (i) an ECL co-reactant composition provided herein and (ii) an ECL label; (b) applying a voltage to the electrode; and (c) generating ECL. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the present disclosure provides a method for generating electrochemiluminescence (ECL), the method comprising: (a) contacting an electrode with: (i) a TEA composition comprising TEA, an ionic component, and optionally a surfactant; and (ii) an ECL label; (b) applying a voltage to the electrode; and (c) generating ECL. In an embodiment, the method further comprises detecting the generated ECL. In embodiments, the method further comprises measuring the ECL produced, thereby quantifying the amount of ECL label. In embodiments, the electrode is present on the surface.
[0250] In an embodiment, the present disclosure provides a method for quantifying the amount of ECL labeling in a sample, the method comprising: (a) contacting an electrode with: (i) an ECL co-reactant composition as provided herein or a TEA composition as provided herein; and (ii) the sample comprising the ECL labeling; (b) applying a voltage to the electrode; (c) generating ECL; (d) measuring the ECL; and (e) quantifying the amount of the ECL labeling from the measured ECL. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0251] In an embodiment, ECL is produced by the reaction between an ECL co-reactant (e.g., TEA, tBDEA, MDEA and / or DEA-PS) and an ECL label in the composition herein. In an embodiment, the ECL label is present on an ECL-labeled component. In an embodiment, the ECL label is present in a sample. In an embodiment, the sample includes an ECL-labeled component. In an embodiment, the ECL-labeled component includes a detection reagent. In an embodiment, the sample includes a binding partner of the ECL-labeled component. In an embodiment, the ECL-labeled component includes a binding partner of the detection reagent. In an embodiment, the detection reagent is part of a binding complex comprising a detection reagent, an analyte, and a capture reagent, wherein the capture reagent includes a binding partner to a binding reagent immobilized on a surface. In an embodiment, the ECL-labeled component is an oligonucleotide probe complementary to an extension primer, which is connected to a detection reagent (e.g., a detection antibody) bound to a target analyte (e.g., a peptide or protein). Detection reagents and their binding partners are further described herein. In an embodiment, the ECL-labeled component is present in a binding complex, and the method further comprises detecting the binding complex by detecting the generated ECL. In embodiments, the method comprises contacting an electrode with a sample comprising a binding partner for an ECL-labeled component, wherein the ECL-labeled component and the binding partner form a binding complex, and the method further comprises detecting the binding complex by detecting the generated ECL. In embodiments, the method comprises measuring the generated ECL, thereby quantifying the amount of the ECL-labeled component and / or the binding complex.
[0252] In an embodiment, each of the sample, ECL co-reactant composition or TEA composition and ECL-labeled component provided herein is dry. In an embodiment, each of the sample, ECL co-reactant composition or TEA composition and ECL-labeled component provided herein is liquid. In an embodiment, one or more of the sample, ECL co-reactant composition or TEA composition and ECL-labeled component provided herein is dry, and the remaining components are liquid. For example, the sample is liquid, and one or two of the ECL co-reactant composition or TEA composition and ECL-labeled component provided herein are dry. In an embodiment comprising a liquid component and a dry component, the liquid component reconstitutes the dry component. In an embodiment, the method further comprises contacting the electrode with a liquid diluent, thereby reconstructing the dry component in the liquid. In an embodiment, the dry component is present on the surface. In an embodiment, the ECL co-reactant composition is dry and present on the surface. In an embodiment, the TEA composition is dry and present on the surface. In an embodiment, the ECL-labeled component is dry and present on the surface. Compositions in dry form are described herein. In an embodiment, the ECL-labeled component is a detection reagent comprising an ECL label. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0253] In embodiments, the ECL-labeled component of the binding complex is a first copy of a detection reagent comprising an ECL label. In embodiments, the binding complex comprises a first copy of a detection reagent and a binding reagent immobilized on a surface. Binding reagents are further described herein. In embodiments, the method further comprises forming a binding complex. In embodiments, the binding complex is formed before or during step (a) of the method.
[0254] In an embodiment, the binding complex is formed by incubating an assay mixture comprising a binding reagent, a first copy of the detection reagent, and a second copy of the detection reagent comprising an ECL label under conditions wherein the binding complex is formed on the surface and a second copy of the detection reagent is retained in solution. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0255] In an embodiment, a binding complex is formed by incubating an assay mixture comprising a binding reagent, a first copy of a detection reagent, a second copy of a detection reagent comprising an ECL label, and an ECL co-reactant composition or TEA composition as provided herein under conditions wherein a binding complex is formed on the surface and a second copy of the detection reagent is retained in solution. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the composition comprises TEA. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0256] In an embodiment, a binding complex is formed by combining a sample with a first copy of a detection reagent, a second copy of a detection reagent comprising an ECL label, and an ECL co-reactant composition or TEA composition as provided herein, thereby forming an assay mixture; and contacting the assay mixture with the binding reagent under conditions wherein the binding complex is formed on the surface and the second detection reagent remains in solution. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0257] In embodiments, the binding complex further comprises an analyte. Analytes are further described herein. In embodiments, the binding reagent and the detection reagent each specifically bind to the analyte. In embodiments, the method comprises detecting the analyte by detecting the generated ECL. In embodiments, the method comprises measuring the generated ECL, thereby quantifying the amount of the analyte.
[0258] In an embodiment, the ECL label comprises an electrochemiluminescent organometallic complex. In an embodiment, the electrochemiluminescent organometallic complex comprises ruthenium, osmium, iridium, rhenium and / or a lanthanide metal. In an embodiment, the ECL label comprises ruthenium. In an embodiment, the ECL label comprises ruthenium(II) tris-bipyridine. In an embodiment, the electrochemiluminescent organometallic complex comprises a substituted or unsubstituted bipyridine or a substituted or unsubstituted phenanthroline. In an embodiment, the ECL label comprises a substituted bipyridine. In an embodiment, the ECL label comprises an organometallic complex comprising at least one substituted bipyridine ligand, wherein the substituted bipyridine ligand comprises at least one sulfonate group. In an embodiment, the ECL label comprises an organometallic complex comprising at least two substituted bipyridine ligands, wherein each substituted bipyridine ligand comprises at least one sulfonate group. In an embodiment, the substituted bipyridine ligand comprising at least one sulfonate group is a compound of Formula I. In an embodiment, the ECL label comprises a compound of Formula II.
[0259] In embodiments, the compositions herein are used in ECL-based binding assays, e.g., for detecting and / or quantifying an analyte of interest and / or a binding complex comprising an analyte. In embodiments, the binding complex is formed, e.g., on a surface comprising an electrode, and the binding complex comprises an ECL label capable of producing ECL when contacted with an ECL co-reactant as described herein. Binding assay formats include, but are not limited to: (1) direct binding assays, in which the analyte of interest is labeled with an ECL label, and a binding reagent that is a binding partner of the analyte is immobilized to a surface, and a binding complex is formed by direct binding of the binding reagent and the labeled analyte; (2) sandwich binding assays, in which both the immobilized binding reagent and the detection reagent comprising an ECL label are binding partners of the analyte, and the analyte binds to both binding partners to form a binding complex; (3) competitive binding assays, in which the immobilized binding reagent is a binding partner of the analyte, and the labeled detection reagent is a competitor (e.g., the analyte or a structural analog of the analyte) that competes with the immobilized binding reagent for binding to the analyte, or alternatively, the labeled detection reagent is a binding partner of the analyte, and the immobilized binding reagent is a competitor that competes with the detection reagent for binding to the analyte. In competitive binding assays, the amount of labeled binding complex formed by direct binding of the immobilized binding reagent and the labeled detection reagent decreases as the amount of analyte increases. Binding assays are further described in, e.g., WO 2014 / 165061; WO 2014 / 160192; WO 2015 / 175856; US 9,618,510; US 10,114,015; US 10,408,823; US 2017 / 0168047; and US 2019 / 0011441, each of which is herein incorporated by reference in its entirety.
[0260] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) contacting a liquid sample with a surface comprising an ECL co-reactant composition or a TEA composition as provided herein, wherein the liquid sample comprises an ECL-labeled component; or wherein the liquid sample comprises a binding partner of an ECL-labeled component, and the method further comprises contacting the surface with the ECL-labeled component, thereby forming a binding complex on the surface comprising the ECL-labeled component; (b) applying a voltage to the surface to generate ECL; and (c) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant. In an embodiment, the surface comprises an electrode. In an embodiment, the ECL-labeled component comprises a detection reagent comprising an ECL label. In an embodiment, the ECL-labeled component comprises a detection reagent comprising an ECL label, and the binding complex comprises a binding reagent and a detection reagent. In an embodiment, the ECL-labeled component comprises a binding partner of the detection reagent, wherein the binding partner comprises an ECL label. In an embodiment, the ECL-labeled component comprises a binding partner of the detection reagent, and the binding complex comprises a binding reagent, a detection reagent, and a binding partner. Detection reagents and binding partners are further described herein. In an embodiment, the detection reagent and the ECL-labeled component comprise complementary oligonucleotides. In an embodiment, the binding complex further comprises an analyte. In an embodiment, the binding reagent and the detection reagent each specifically bind to the analyte.
[0261] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) contacting a liquid sample with a surface comprising an ECL-labeled component and an ECL co-reactant composition or TEA composition as provided herein, wherein the liquid sample comprises a binding partner for the ECL-labeled component, thereby forming a binding complex on the surface comprising the ECL-labeled component; (b) applying a voltage to the surface to generate ECL; and (c) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant. In an embodiment, the surface comprises an electrode. In an embodiment, the ECL-labeled component comprises a detection reagent comprising an ECL label. In an embodiment, the ECL-labeled component comprises a detection reagent comprising an ECL label, and the binding complex comprises a binding reagent and a detection reagent. In an embodiment, the ECL-labeled component comprises a binding partner of the detection reagent, wherein the binding partner comprises an ECL label. In an embodiment, the ECL-labeled component comprises a binding partner of the detection reagent, and the binding complex comprises a binding reagent, a detection reagent, and a binding partner. Detection reagents and binding partners are further described herein. In an embodiment, the detection reagent and the ECL-labeled component comprise complementary oligonucleotides. In an embodiment, the binding complex further comprises an analyte. In an embodiment, the binding reagent and the detection reagent each specifically bind to the analyte.
[0262] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) forming a binding complex on a surface, wherein the binding complex comprises an ECL-labeled component; (b) contacting the binding complex with an ECL co-reactant composition or a TEA composition provided herein; (c) applying a voltage to the surface to generate ECL; and (d) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant. In an embodiment, the surface comprises an electrode. In an embodiment, the ECL-labeled component comprises a detection reagent comprising an ECL label. In an embodiment, the ECL-labeled component comprises a detection reagent comprising an ECL label, and the binding complex comprises a binding reagent and a detection reagent. In an embodiment, the ECL-labeled component comprises a binding partner of the detection reagent, wherein the binding partner comprises an ECL label. In an embodiment, the ECL-labeled component comprises a binding partner of the detection reagent, and the binding complex comprises a binding reagent, a detection reagent, and a binding partner. Detection reagents and binding partners are further described herein. In an embodiment, the detection reagent and the ECL-labeled component comprise complementary oligonucleotides. In an embodiment, the binding complex further comprises an analyte. In an embodiment, the binding reagent and the detection reagent each specifically bind to the analyte.
[0263] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) forming a binding complex on a surface, wherein the surface comprises an electrode, and wherein the binding complex comprises a binding reagent immobilized on the surface and a detection reagent comprising an electrochemiluminescent (ECL) label; (b) contacting the binding complex with an ECL co-reactant composition or a TEA composition provided herein; (c) applying a voltage to the surface to generate ECL; and (d) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the binding complex further comprises an analyte, and the binding reagent and the detection reagent each specifically bind to the analyte. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant. In embodiments, the binding complex further comprises an analyte. In embodiments, the binding reagent and the detection reagent each specifically bind to the analyte.
[0264] In an embodiment, the present disclosure provides a method for detecting an analyte of interest in a sample, the method comprising: (a) contacting the sample with: (i) a surface comprising a binding reagent, wherein the binding reagent specifically binds to the analyte; and (ii) a detection reagent that specifically binds to the analyte, wherein the detection reagent comprises an electrochemiluminescent (ECL) label, thereby forming a binding complex on the surface, the binding complex comprising the binding reagent, the analyte, and the detection reagent; (b) contacting the binding complex on the surface with an ECL co-reactant composition or a TEA composition provided herein; (c) applying a voltage to the surface to generate ECL; and (d) detecting the generated ECL, thereby detecting the analyte. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant. In an embodiment, the surface comprises an electrode. In an embodiment, the analyte of interest is an oligonucleotide, and the detection reagent that specifically binds to the analyte is an oligonucleotide probe, said oligonucleotide probe comprising an ECL label and a quenching moiety that quenches the ECL signal at least when the ECL-labeled oligonucleotide probe is not hybridized to a complementary oligonucleotide. In an embodiment, the ECL-labeled oligonucleotide probe comprises a stem-loop or hairpin structure, an ECL label, and a quenching moiety, wherein the quenching moiety is proximal to the ECL label and quenches the ECL label when the ECL-labeled oligonucleotide probe is in a stem-loop or hairpin configuration, but does not quench the ECL label when the stem-loop or hairpin structure is in an open configuration (e.g., as in Figure 14 and 20 In an embodiment, an ECL-labeled oligonucleotide probe having a stem-loop or hairpin structure is an ECL-labeled molecular beacon probe. In an embodiment, the ECL-labeled oligonucleotide probe comprises an ECL label and a quencher, and when the probe is in a linear configuration (e.g., not in a stem-loop or hairpin configuration), the ECL label and the quencher are sufficiently close to each other on the probe so that the quencher quenches the ECL signal regardless of whether the probe is hybridized to a complementary oligonucleotide (e.g., as in Figure 21 ).
[0265] In embodiments, the present disclosure provides a method for detecting an analyte of interest in a sample, the method comprising contacting the sample with: (i) a surface comprising a binding reagent, wherein the binding reagent specifically binds to a binding complex comprising the analyte (e.g., a peptide); (ii) a capture reagent (e.g., an antibody) that specifically binds to the analyte, wherein the capture reagent additionally comprises a binding partner to the binding reagent (e.g., biotin / streptavidin); (iii) a detection reagent that specifically binds to the analyte, wherein the detection reagent comprises an oligonucleotide primer (e.g., an oligonucleotide-labeled antibody); (iv) a template oligonucleotide; and (v) an ECL-labeled oligonucleotide probe. In embodiments, the capture reagent and the detection reagent bind to the analyte, the primer binds to the template oligonucleotide, the primer is extended by amplification of the template oligonucleotide, and the ECL-labeled oligonucleotide probe binds to the extended primer oligonucleotide (e.g., as in Figure 20 ). In an embodiment, the binding complex comprises a capture reagent comprising a binding partner, an analyte, and a detection reagent comprising an extended oligonucleotide primer. The surface is contacted with an ECL co-reactant composition or a TEA composition as provided herein, a voltage is applied to the surface to generate ECL, and the generated ECL is detected to detect the analyte. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant. In an embodiment, the surface comprises an electrode. In an embodiment, the ECL-labeled oligonucleotide probe is a molecular beacon probe.
[0266] As discussed herein, the compositions provided herein can be used for ECL-based assays that do not require a washing step. A "washing step" used in the context of an ECL-based assay performed on a surface refers to adding a wash buffer to the surface to remove undesirable components, such as excess, non-specifically bound or unbound reagents (e.g., detection reagents and / or ECL markers) and / or unbound or non-specifically bound components of the sample from the assay reaction mixture. In one example, a biological sample can contain an analyte of interest and various other biological materials that are not of interest and do not specifically bind to a binding reagent, and a washing step can remove such components from the reaction mixture. In an embodiment, the composition includes TEA. In an embodiment, the composition includes TEA, an ionic component, and optionally a surfactant. In a "washing" assay, a washing step is typically used to remove unbound ECL markers before detecting the ECL markers on the surface. If the detection method can effectively distinguish between ECL markers bound to the surface (e.g., as part of a binding complex to be detected) or unbound "free" ECL markers in the solution, the washing step can be eliminated. "No-wash" assay formats that eliminate wash steps are often advantageous, as wash steps can be difficult or tedious to perform in many cases. However, no-wash assay formats are often difficult to develop due to high background ECL signal resulting from incomplete differentiation of free ECL label from bound ECL label present in the reaction mixture. Even in assays that employ wash steps, good differentiation between bound and free ECL label is advantageous because it provides greater robustness to wash inefficiencies or quality variations by offering tolerance to low-level free label contamination that may be associated with poor-quality washes.
[0267] As discussed herein, in ECL-based assays performed on solid surfaces (e.g., solid electrode surfaces), the compositions herein surprisingly distinguish between free ECL labels relative to bound ECL labels. In an embodiment, the compositions herein increase the ratio of the ECL signal from the bound label to the ECL signal from the free label. Thus, the compositions herein provide improved assay performance, particularly when measuring low affinity interactions, which require the presence of high concentrations of ECL labels in the reaction, but are also expected to suffer significant signal loss due to dissociation of the binding complex during the wash step. In an embodiment, the composition comprises TEA. In an embodiment, the composition comprises TEA, an ionic component, and optionally a surfactant.
[0268] Without being bound by theory, it is believed that the compositions herein and ECL co-reactants (e.g., TEA) reduce the distance from the solid electrode surface at which ECL is generated by the ECL label. This, in turn, increases the signal of the bound label (which is held in close proximity to the electrode) relative to the signal of the free label (which is distributed throughout the solution above the electrode). The increased signal from the bound label can also be characterized by an "effective excitation length," which is the maximum distance over which the free ECL label can be excited. The "effective excitation length" is affected by the following factors: (1) the distance that short-lived intermediates involved in ECL generation (e.g., oxidation products of the ECL co-reactant) can diffuse from the electrode before being consumed in side reactions (a function of the lifetime and diffusion constant of these intermediates); and (2) the rate at which free label or unbound labeled reagent diffuses to a region close enough to the electrode to participate in reactions with these reactive intermediates (a function of the diffusion constant of the unbound ECL label or labeled reagent). In the methods of using the compositions herein, the effective excitation length is reduced by greater than 2 times, greater than 3 times, greater than 4 times, greater than 5 times, greater than 9 times, greater than 7 times, greater than 8 times, greater than 9 times, or greater than 10 times compared to a composition comprising TPA. In embodiments, the composition comprises TEA. In embodiments, the composition comprises TEA, an ionic component, and optionally a surfactant.
[0269] In an embodiment, the method herein does not include a washing step. In an embodiment in which the method detects a bound complex, the method does not include a washing step before, during, or after forming a bound complex on the surface. In an embodiment in which the method detects an analyte of interest in a sample, the method does not include a washing step before, during, or after contacting the sample with (i) a surface comprising a binding reagent and (ii) a detection reagent that specifically binds to the analyte, wherein the binding reagent specifically binds to the analyte. In an embodiment, the method does not include a washing step before, during, or after contacting the bound complex with a composition. In an embodiment, the method does not include a washing step before, during, or after applying a voltage to the surface to generate ECL. In an embodiment, the method does not include a washing step before or during detection of the generated ECL. In an embodiment, the composition includes TEA. In an embodiment, the composition includes TEA, an ionic component, and optionally a surfactant.
[0270] In an embodiment, the method herein includes a washing step. In an embodiment in which the method detects a bound complex, the method includes a washing step before, during, or after forming the bound complex on the surface. In an embodiment in which the method detects an analyte of interest in a sample, the method includes a washing step before, during, or after contacting the sample with (i) a surface comprising a binding reagent and (ii) a detection reagent that specifically binds to the analyte, wherein the binding reagent specifically binds to the analyte. In an embodiment, the method includes a washing step before, during, or after contacting the bound complex with a composition. In an embodiment, the method includes a washing step before, during, or after applying a voltage to the surface to generate ECL. In an embodiment, the method includes a washing step before or during detecting the generated ECL. In an embodiment, the composition includes TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the composition includes TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition includes TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition includes TEA.
[0271] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) forming an assay mixture by combining a sample with: (i) an ECL co-reactant composition or a TEA composition as provided herein; and (ii) a detection mixture comprising at least two copies of a detection reagent, wherein each copy of the detection reagent comprises an ECL label; (b) contacting the assay mixture with a binding reagent immobilized on a surface under conditions wherein (I) a binding complex is formed on the surface (the binding complex comprising the binding reagent and a first copy of the detection reagent); and (II) the second copy of the detection reagent remains in solution, wherein the surface optionally comprises an electrode; (c) applying a voltage to the surface to generate ECL; and (d) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the surface comprises an electrode. In an embodiment, the second copy of the detection reagent is not removed before any of steps (b) to (d). In an embodiment, the second copy of the detection reagent is not removed before step (b). In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0272] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) incubating an assay mixture comprising (i) a binding complex formed on a surface (the binding complex comprising a binding reagent and a first copy of a detection reagent); and (ii) a second copy of the detection reagent remaining in solution, the assay mixture comprising (i) a binding reagent immobilized on a surface, wherein the surface optionally comprises an electrode; and (ii) a detection mixture comprising at least two copies of a detection reagent, wherein each copy of the detection reagent comprises an electrochemiluminescent (ECL) label; (b) contacting the binding complex with an ECL co-reactant composition or a TEA composition provided herein; (c) applying a voltage to the surface to generate ECL; and (d) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the surface comprises an electrode. In an embodiment, the method further comprises washing the surface prior to any of steps (b) to (d), thereby removing the second copy of the detection reagent. In an embodiment, the second copy of the detection reagent is not removed prior to any of steps (b) to (d). In an embodiment, the second copy of the detection reagent is not removed prior to step (b). In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0273] In an embodiment, the present disclosure provides a method for detecting a binding complex, the method comprising: (a) incubating an assay mixture comprising (i) a binding complex formed on a surface (the binding complex comprising a binding reagent and a first copy of a detection reagent); and (ii) a second copy of the detection reagent remaining in solution, the assay mixture comprising (i) a binding reagent immobilized on a surface, wherein the surface optionally comprises an electrode; and (ii) a detection mixture comprising at least two copies of a detection reagent, wherein each copy of the detection reagent comprises an electrochemiluminescent (ECL) label; and (iii) an ECL co-reactant composition or a TEA composition as provided herein; (b) applying a voltage to the surface to generate ECL; and (c) detecting the generated ECL, thereby detecting the binding complex. In an embodiment, the surface comprises an electrode. In an embodiment, the method further comprises washing the surface prior to any of steps (b) or (c), thereby removing the second copy of the detection reagent. In an embodiment, the second copy of the detection reagent is not removed prior to any of steps (b) or (d). In an embodiment, the second copy of the detection reagent is not removed prior to step (b). In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, tBDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA, BDEA, MDEA, DEA-PS, or a combination thereof. In an embodiment, the ECL co-reactant composition comprises TEA. In an embodiment, the TEA composition comprises TEA, an ionic component, and optionally a surfactant.
[0274] In embodiments, the binding complex further comprises an analyte, and the binding reagent and the first copy of the detection reagent each specifically bind to the analyte.
[0275] In embodiments, at least two copies of a binding reagent are immobilized on a surface, and wherein a first copy of the binding reagent forms a complex with a first copy of the detection reagent, and a second copy of the binding reagent is bound to a competitor such that the second copy of the binding reagent does not form a complex with the second copy of the detection reagent. In embodiments, at least two copies of a binding reagent are immobilized on a surface, and wherein a first copy of the binding reagent forms a complex with a first copy of the detection reagent, and a second copy of the detection reagent is bound to a competitor such that the second copy of the binding reagent does not form a complex with the second copy of the detection reagent. Competitor and competitive assay formats are further described herein.
[0276] In embodiments, the binding reagent binds to the first copy of the detection reagent to form a binding complex.
[0277] In an embodiment, the binding reagent includes an antibody or its antigen-binding fragment, an antigen, a ligand, a receptor, an oligonucleotide, a hapten, an epitope, a mimotope or an aptamer. In an embodiment, the binding reagent is an antibody or its variant, comprising its antigen / epitope binding portion, an antibody fragment or derivative, an antibody analog, an engineered antibody or a substance that binds to an antigen in a manner similar to an antibody. In an embodiment, the binding reagent includes at least one heavy chain or light chain complementary determining region (CDR) of an antibody. In an embodiment, the binding reagent includes at least two CDRs from one or more antibodies. In an embodiment, the binding reagent is an antibody or its antigen-binding fragment. In an embodiment, the binding reagent specifically binds to an analyte. As used herein, "specific binding" means that relative to random, unrelated substances, an agent (e.g., a binding reagent) preferentially binds to its binding partner (e.g., an epitope of an analyte). In an embodiment, the binding reagent is an antibody or its antigen-binding fragment comprising a binding domain that specifically binds to the epitope of an analyte.
[0278] In an embodiment, the binding reagent is fixed to the surface. In an embodiment, the binding reagent is directly fixed to the surface. In an embodiment, the binding reagent is indirectly fixed to the surface via the binding reagent and a secondary binding partner on the surface. Exemplary secondary binding partners include but are not limited to complementary oligonucleotides, receptor-ligand pairs, antigen-antibody pairs, hapten-antibody pairs, epitope-antibody pairs, mimotope-antibody pairs, aptamer-target molecule pairs, hybridization partners, intercalator-target molecule pairs, cross-reactive moieties (e.g., thiol and maleimide or iodoacetamide; aldehyde and hydrazide; or azide and alkyne or cycloalkyne).
[0279] In an embodiment, the detection reagent comprises an antibody or its antigen detection fragment, an antigen, a ligand, a receptor, an oligonucleotide, a hapten, an epitope, a mimotope or an aptamer. In an embodiment, the detection reagent is an antibody or its variant, comprising its antigen / epitope detection portion, an antibody fragment or derivative, an antibody analog, an engineered antibody or a substance that binds to an antigen in a manner similar to an antibody. In an embodiment, the detection reagent comprises at least one heavy chain or light chain complementary determining region (CDR) of an antibody. In an embodiment, the detection reagent comprises at least two CDRs from one or more antibodies. In an embodiment, the detection reagent is an antibody or its antigen detection fragment. In an embodiment, the detection reagent specifically binds to the analyte. In an embodiment, the detection reagent is an antibody or its antigen binding fragment comprising a binding domain that specifically binds to an epitope of the analyte. In an embodiment, the detection reagent binds to a different epitope of the analyte compared to the binding reagent. In an embodiment, both the binding reagent and the detection reagent are antibodies or their antigen binding fragments.
[0280] In embodiments, the detection reagent comprises an ECL label. In embodiments, the ECL label comprises an electrochemiluminescent organometallic complex. In embodiments, the organometallic complex comprises ruthenium, osmium, iridium, rhenium and / or a lanthanide metal. In embodiments, the organometallic complex comprises a substituted or unsubstituted bipyridine or a substituted or unsubstituted phenanthroline. In embodiments, the ECL label comprises ruthenium. In embodiments, the ECL label comprises ruthenium(II) tris-bipyridine. In embodiments, the ECL label comprises a substituted bipyridine. In embodiments, the ECL label comprises an organometallic complex comprising at least one substituted bipyridine ligand, wherein the substituted bipyridine ligand comprises at least one sulfonate group. In embodiments, the ECL label comprises an organometallic complex comprising at least two substituted bipyridine ligands, wherein each substituted bipyridine ligand comprises at least one sulfonate group. In embodiments, the substituted bipyridine ligand comprising at least one sulfonate group is a compound of Formula I. In embodiments, the ECL label comprises a compound of Formula II. Exemplary ECL labels are provided in US 5,714,089; US 6,136,268; US 6,316,607; US 6,468,741; US 6,479,233; US 6,808,939; and US 9,499,573, each of which is incorporated herein by reference in its entirety.
[0281] In an embodiment, the binding reagent and / or detection reagent is directly bound to the analyte. For example, the binding reagent and detection reagent are each an antibody or an antigen binding fragment thereof that specifically binds to an epitope on the analyte. In an embodiment, the binding reagent and / or detection reagent is indirectly bound to the analyte through a secondary interaction. In an embodiment, the analyte is connected to a binding partner of the binding reagent and / or detection reagent. For example, the binding reagent and / or detection reagent includes streptavidin, and the analyte is connected to biotin. Other examples of binding partners that can be identified by secondary interactions include, for example, avidin-biotin, streptavidin-biotin, antibody-hapten, antibody-epitope tag, nucleic acid-complementary nucleic acid, aptamer-aptamer target, and receptor-ligand.
[0282] In an embodiment, the surface comprises a porous plate. In an embodiment, the surface comprises particles. In an embodiment, the surface comprises an assay box. In an embodiment, the surface comprises the surface of a slide, a chip, a hole, an assay cell or a flow cell, a tube, a channel, a bead or a microparticle. In an embodiment, the surface comprises particles, and the method further comprises collecting the particles on another surface and applying a voltage to the particles on the other surface. In an embodiment, the particles are beads (such as magnetic beads), and the method further comprises collecting beads on a magnetized plate, wherein the plate comprises electrodes, and applying a voltage to the plate. In an embodiment, the surface and / or the other surface comprises electrodes. In an embodiment, the electrodes are carbon electrodes, platinum electrodes, gold electrodes or silver electrodes. In an embodiment, the electrodes are carbon ink electrodes. In an embodiment, the substrate surface comprises electrodes. In an embodiment, the substrate comprises an electrode layer coated thereon.
[0283] In an embodiment, the method includes measuring the amount of the analyte of interest or the binding complex in the sample. The method of using the ECL signal of the measured amount to determine the quantity and / or concentration of the ECL labeling (or analyte or binding complex) in the binding assay based on ECL is known to those of ordinary skill in the art, and includes, for example, using calibration standards and / or calibration curves to establish the relationship between the quantity and / or concentration of ECL signal and ECL labeling and / or analyte. Calibration can be carried out at different times, for example, during the development of the method, during the qualitative period of a particular batch of assay materials and / or when measuring. Calibration can also be carried out using calculations based on the known physical and chemical behavior of assay components and instruments.
[0284] Method herein can be used for testing the various samples that may contain the analyte of interest.In an embodiment, sample is a biological sample.In an embodiment, sample is derived from cell (living cell or dead cell), immortalized cell, cell-derived product, cell fragment, cell fraction, cell lysate (fractionated or unfractionated), eukaryotic cell, prokaryotic cell, organelle, nucleus and its fraction, cell membrane, hybridoma, cell culture supernatant (for example, from the supernatant of the organism that produces antibody such as hybridoma), cytoskeleton, protein complex, structural biological component, as skeletal components such as ligament and tendon, hair, fur, feather, hair fraction, skin, dermis, endothelium, mammalian fluid, secretion, excreta, whole blood, blood plasma, serum, sputum, tear, lymph, synovial fluid, pleural effusion, urine, sweat, cerebrospinal fluid, ascites, milk, feces, bronchial lavage fluid, saliva, amniotic fluid, nasal secretion, vaginal secretion, surface biopsy, sperm, seminal fluid (semen / seminal Fluid), wound secretions and excretions, mucosal swabs, tissue aspirates, tissue homogenates, or extractions, purifications, or dilutions thereof. In embodiments, the sample is derived from a plant, plant byproduct, soil, water source, oil, sewage, or environmental sample. In embodiments, the sample further comprises water, an organic solvent (e.g., acetonitrile, dimethyl sulfoxide, dimethylformamide, n-methyl-pyrrolidone, alcohol, or a combination thereof), EDTA, heparin, citrate, or a combination thereof. The sample may be obtained from a single source as described herein, or may contain a mixture from two or more sources.
[0285] Analytes that can be measured using the methods of the present disclosure include, but are not limited to, whole cells, cell surface antigens, subcellular particles (e.g., organelles or membrane fragments), exosomes, extracellular vesicles, liposomes, membrane vesicles, viruses, prions, dust mites or fragments thereof, viroids, antibodies, antigens, haptens, fatty acids, nucleic acids (and synthetic analogs), proteins (and synthetic analogs), lipoproteins, polysaccharides, inhibitors, cofactors, haptens, cell receptors, receptor ligands, lipopolysaccharides, glycoproteins, peptides, polypeptides, enzymes, enzyme substrates, enzyme products, second messengers, cellular metabolites, hormones, pharmaceutical agents, synthetic organic molecules, organometallic molecules, sedatives, barbiturates, alkaloids, steroids, vitamins, amino acids, sugars, lectins, recombinant or derivatized proteins, biotin, avidin, streptavidin, or inorganic molecules present in a sample. Activities that can be measured include, but are not limited to, the following: phosphorylase, phosphatase, esterase, transglutaminase, nucleic acid damaging activity, transferase, oxidase, reductase, dehydrogenase, glycosidase, ribosome, protein processing enzyme (e.g., protease, kinase, protein phosphatase, ubiquitin-protein ligase, etc.), nucleic acid processing enzyme (e.g., polymerase, nuclease, integrase, ligase, helicase, telomerase, etc.), cell receptor activation, second messenger system activation, etc.
[0286] Whole cells can be animals, plants, or bacteria, and can be living or dead. Examples include plant pathogens, such as fungi and nematodes. The term "subcellular particle" has a simple and common meaning as understood in accordance with the specification, and encompasses, for example, subcellular organelles, such as membrane particles from damaged cells, fragments of cell walls, ribosomes, multienzyme complexes, and other particles that can be derived from living organisms. Nucleic acids include, for example, chromosomal DNA, plasmid DNA, viral DNA, and recombinant DNA derived from a variety of sources. Nucleic acids also include RNA, such as messenger RNA, ribosomal RNA, and transfer RNA. Polypeptides include, for example, enzymes, transporters, receptor proteins, and structural proteins (such as viral coat proteins). In embodiments, the polypeptide is an enzyme or an antibody. In embodiments, the polypeptide is a monoclonal antibody. Hormones include, for example, insulin and T4 thyroid hormone. Pharmaceutical agents include, for example, cardiac glycosides. Synthetic substances that are chemically similar to biological materials, such as synthetic polypeptides, synthetic nucleic acids, and synthetic membranes, vesicles, and liposomes, are within the scope of this disclosure. The foregoing is not intended to be a complete list of biological substances applicable to the present disclosure, but is merely intended to illustrate the broad scope of this disclosure.
[0287] In embodiments, the methods herein are multiplex methods capable of detecting a variety of binding complexes and / or analytes. In embodiments, a multiplex method detects a variety of binding complexes and / or analytes simultaneously. In embodiments, a multiplex method comprises repeating one or more method steps to measure a variety of binding complexes and / or analytes. In embodiments, each of the method steps is performed in parallel for each binding complex and / or analyte. In embodiments where the method detects a variety of binding complexes, each binding complex comprises a different binding and / or detection reagent. In embodiments where the method detects a variety of analytes, each analyte is bound to a different binding and / or detection reagent. In embodiments, by contacting a surface with a sample comprising a variety of analytes, the binding of each analyte to its corresponding binding reagent is performed in parallel.
[0288] In an embodiment, the multiplex method does not include a wash step. Due to the increased amount of detection reagent present in the assay mixture, and therefore the increased amount of ECL label in the solution, resulting in a high background ECL signal, multiplex non-wash assays are particularly challenging. The ECL co-reactants herein have surprisingly good differentiation between bound ECL label and free ECL label in multiplex assay formats (including multiple non-wash assays), thereby providing high ECL signal and low background. In an embodiment, the ECL co-reactant is TEA.
[0289] In an embodiment, the surface comprises a plurality of binding domains, and each binding complex is formed in a different binding domain. In an embodiment, the plurality of binding domains are on a single surface. In an embodiment, the surface comprises a multi-well plate, and each binding domain is in a different well. In an embodiment, the surface comprises a well of a multi-well plate, and each binding domain is in a separate portion of the well. In an embodiment, the plurality of binding domains are on one or more surfaces. In an embodiment, the surface comprises particles, and each binding domain is on a different particle. In an embodiment, the particles are arranged in a particle array. In an embodiment, the particles are coded to allow identification of specific particles and to distinguish each binding domain.
[0290] In embodiments, each binding domain comprises a targeting agent capable of binding to the complement of the targeting agent, and each binding agent comprises a complementary linking agent capable of binding to a linking agent. In embodiments, the binding agent is immobilized in the binding domain by: (1) binding the binding agent to the complement of the targeting agent linked to the linking agent via the complementary linking agent; and (2) binding the product of (1) to a binding domain comprising a targeting agent, wherein (i) each binding domain comprises a different targeting agent, and (ii) each targeting agent complement selectively binds to one of the targeting agents, thereby immobilizing each binding agent to its associated binding domain.
[0291] In an embodiment, an optional bridging agent (which is a binding partner for both the linking agent and the complementary linking agent) bridges the linking agent and the complementary linking agent such that each binding agent bound to its corresponding targeting agent complement contacts the binding domain and is bound to its corresponding targeting agent via the bridging agent, the targeting agent complement on each of the binding agents, and the targeting agent on each of the binding domains.
[0292] In an embodiment, the targeting agent and the targeting agent complement are two members of a binding partner pair selected from the group consisting of avidin-biotin, streptavidin-biotin, antibody-hapten, antibody-antigen, antibody-epitope tag, nucleic acid-complementary nucleic acid, aptamer-aptamer target, and receptor-ligand. In an embodiment, the targeting agent and the targeting agent complement are cross-reactive moieties, e.g., thiol and maleimide or iodoacetamide; aldehyde and hydrazide; or azide and alkyne or cycloalkyne. In an embodiment, the targeting agent is biotin, and the targeting agent complement is avidin or streptavidin.
[0293] In an embodiment, the linker and the supplementary linker are two members of a binding partner pair selected from the group consisting of avidin-biotin, streptavidin-biotin, antibody-hapten, antibody-antigen, antibody-epitope tag, nucleic acid-complementary nucleic acid, aptamer-aptamer target, and receptor-ligand. In an embodiment, the linker and the supplementary linker are cross-reactive moieties, e.g., thiol and maleimide or iodoacetamide; aldehyde and hydrazide; or azide and alkyne or cycloalkyne. In an embodiment, the linker is avidin or streptavidin, and the supplementary linker is biotin. In an embodiment, the targeting agent and the targeting agent complement are complementary oligonucleotides. In an embodiment, the targeting agent complement is streptavidin, the targeting agent is biotin, and the linker and the supplementary linker are complementary oligonucleotides.
[0294] In embodiments including a bridging agent, the bridging agent is streptavidin or avidin, and the linking agent and the supplemental linking agent are each biotin.
[0295] In an embodiment, the present disclosure provides a method for producing a composition comprising combining an ECL co-reactant, an ionic component, and a surfactant. In embodiments, the ECL coreactant is tributylamine (TBA), (dibutyl)aminoethanol (DBAE), (diethyl)aminoethanol (DEAE), triethanolamine (TEA), butyldiethanolamine (BDEA), propyldiethanolamine (PDEA), ethyldiethanolamine (EDEA), methyldiethanolamine (MDEA), tert-butyldiethanolamine (tBDEA), dibutylamine (DBA), butylethanolamine (BEA), diethanolamine (DEA), dibutylamine propyl sulfonate (DBA-PS), dibutylamine butyl sulfonate (DBA-BS), butylethanolamine propyl sulfonate (BEA-PS), butylethanolamine butyl sulfonate (BEA-BS), diethanolamine propyl sulfonate (DEA-PS), or diethanolamine butyl sulfonate (DEA-BS, also known as 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid).
[0296] In an embodiment, the present disclosure further provides a method for producing a composition, the method comprising combining: triethanolamine (TEA) and an ionic component. In an embodiment, the present disclosure further provides a method for producing a composition, the method comprising combining: triethanolamine (TEA), an ionic component, and a surfactant, wherein the method does not include the addition of an additional pH buffer component. In an embodiment, one or more of the components are provided in a dry form. Ionic components and surfactants suitable for the composition are provided herein, and include, for example, NaCl, KCl, and LiCl (for the ionic component), and poloxamer 407 ( P-407), PEO 18 -PPO72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate and alkyl ether-polyethylene glycol (e.g., PEG (18) tridecyl ether) (for surfactant). TEA, ionic components and surfactants can be included in the concentrations described herein. In an embodiment, the composition produced by the method includes about 1000mM to about 6500mM TEA, about 700 to about 1000mM ionic components and about 0.5mM to about 10mM surfactant. In an embodiment, the composition produced by the method includes about 1200mM to about 1600mM TEA, about 700 to about 1000mM ionic components and about 1mM to about 5mM surfactant.
[0297] In an embodiment, the present disclosure further provides a method of producing a composition, the method comprising combining: tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS) or a combination thereof; an ionic component; and a surfactant. In an embodiment, one or more of the components are provided in dry form. Ionic components and surfactants suitable for the composition are provided herein and include, for example, NaCl, KCl, and LiCl (for the ionic component), and poloxamer 407 ( P-407), PEO 18 -PPO 72 -PEO 18 ( P-123), PEG5-PPG 68 -PEG5( L-121), PPO 26 -PEO5-PPO 26 ( 31R1), ethylenediaminetetra(propoxylate-block-ethoxylate)tetraol ( 701), polyethylene glycol lauryl ether ( L4), polyethylene glycol cetyl ether ( 58), Polysorbate 20 ( 20), 2,4,7,9-tetramethyl-d-decyne-4,7-diol ethoxylate and alkyl ether-polyethylene glycol (e.g., PEG (18) tridecyl ether) (for surfactant). tBDEA and / or MDEA, ionic components and surfactants can be included at the concentrations described herein. In an embodiment, the composition produced by the method includes about 50mM to about 250mM tBDEA, about 50mM to about 250mM MDEA and / or about 50mM to about 250mM DEA-PS, about 700 to about 1000mM ionic components, and about 0.5mM to about 10mM surfactant.
[0298] Method using ECL-labeled oligonucleotide probes
[0299] In some embodiments of the methods disclosed herein (including those described above), the method is based on a novel molecular assay for sensitivity and specificity detection using an ECL-labeled oligonucleotide probe. In an embodiment, the probe includes a quenching portion that quenches the ECL signal at least when the probe is not hybridized with a complementary oligonucleotide. In an embodiment, the probe has a molecular beacon-like design. Without being bound by any theory, it is believed that the ECL signal is most efficiently generated near the electrode surface. In an embodiment, the ECL-labeled oligonucleotide probe is fixed on or near the electrode surface, resulting in a higher signal compared to detecting the ECL-labeled oligonucleotide probe in solution. When the target oligonucleotide hybridized with the ECL-labeled oligonucleotide probe is fixed on the surface, the ECL-labeled oligonucleotide probe will be within the optimal excitation distance. In addition, when the probe includes a quenching portion, the method includes dequenching the probe hybridized with the complementary oligonucleotide without dequenching the probe not hybridized with the complementary oligonucleotide, referred to as selective dequenching. Both fixing and dequenching can result in an increase in signal. In embodiments, selective dequenching comprises hybridizing an ECL-labeled oligonucleotide having a molecular beacon-like design to a complementary oligonucleotide such that the quenching moiety is no longer in proximity to the ECL label. In embodiments, selective dequenching comprises cleaving the quenching moiety only from the probe hybridized to the complementary oligonucleotide, thereby releasing the quenching moiety into solution and allowing the ECL-labeled probe to hybridize to the complementary oligonucleotide.
[0300] In an embodiment, the ECL labeled oligonucleotide probe assay can be combined with a read buffer ECL co-reactant that more selectively excites the ECL label closer to the electrode surface to further enhance the signal from the specific binding event. TEA illustrates this more selective co-reactant, but this group of co-reactants also includes MDEA, BDEA, tBDEA, DEA-PS or a combination thereof. In an embodiment, this group of co-reactants also includes MDEA, tBDEA, DEA-PS or a combination thereof. Without being bound by any theory, it is believed that in this group of co-reactants, for example TEA, free radicals have a short lifespan compared to longer-lived substances such as TPA, resulting in ECL being generated only in the solution very close to the electrode surface and not in the hole. By binding to the fixed complementary oligonucleotide (e.g., Figure 14 、 20 21) hybridization to immobilize the ECL-labeled oligonucleotide probe to the surface, the majority of the signal will be generated by the specifically bound molecular species. A small fraction of co-reactant molecules that diffuse within the excitation distance to activate the ECL label on the ECL-labeled oligonucleotide probe that is not hybridized to the complementary oligonucleotide will generate a quenched ECL signal (e.g., because the molecular beacon-like probe is not in its open form (e.g., as Figure 14 and 20 ), or because the quenching moiety is close to the ECL label (e.g. Figure 21 shown)), and therefore less ECL signal will be generated.
[0301] The low background generated by using ECL-labeled oligonucleotide probes (including a quenching moiety) that are selectively quenched only upon hybridization to a complementary oligonucleotide enables a no-wash assay in which the probe can be added to a read buffer and applied to the immobilized target sequence prior to reading the plate. Without being bound by any theory, it is believed that one or more of the following factors, and in particular assays having all three factors, contribute to improved assay performance and enable assays that do not require a wash step to remove ECL-labeled oligonucleotide probes that have not hybridized to the target oligonucleotide prior to detecting the ECL signal:
[0302] 1. Immobilizing the ECL-labeled oligonucleotide probe near the electrode surface can generate ECL signals more efficiently;
[0303] 2. Selective dequenching of an ECL-labeled oligonucleotide probe hybridized to an immobilized complementary oligonucleotide selectively increases the ECL signal generated for a specific binding event; and / or
[0304] 3. TEA-based reading buffers (or co-reactants with similar short radical lifetimes, such as MDEA, BDEA, tBDEA, and DEA-PS) further enhance the differentiation of signal generation between ECL-labeled oligonucleotide probes hybridized to immobilized complementary oligonucleotides and quenched ECL-labeled oligonucleotide probes in solution.
[0305] In an embodiment, the method comprises using an ECL-labeled oligonucleotide probe as described herein to detect the presence of a binding complex, binding partner, and / or analyte. In an embodiment, the method comprises providing a substrate (e.g., a well, a multi-well plate, a glass slide, etc.) having a surface of a binding reagent and / or binding partner and / or binding complex disclosed herein immobilized thereon. In an embodiment, the substrate surface comprises an electrode. In an embodiment, the substrate comprises an electrode layer coated thereon.
[0306] In an embodiment, fixed binding reagent is exposed to the composition of the binding partner and / or binding complex containing binding reagent.For example, binding partner and / or binding complex is or includes the analyte of interest.Binding reagent is allowed to combine with binding partner and / or binding complex.After binding partner and / or binding complex combine, optionally washing can be carried out to wash unbound binding partner and / or binding complex.In an embodiment, binding partner and / or binding complex includes oligonucleotide.Binding partner and / or binding complex can include oligonucleotide before being exposed to binding reagent, or oligonucleotide can be added to binding partner and / or binding complex after it is combined with binding reagent.For example, before being exposed to binding reagent, or after binding partner and / or binding complex is attached to binding reagent, binding partner and / or binding complex can be labeled with oligonucleotide.In an embodiment, binding partner is the oligonucleotide analyte of interest, and therefore binding partner and oligonucleotide are same. In embodiments, the binding partner and / or binding complex comprises an oligonucleotide analyte, but further comprises an additional oligonucleotide (eg, a tag sequence) added to or hybridized to the oligonucleotide analyte.
[0307] The binding partner and / or binding complex comprising an oligonucleotide is exposed to an ECL-labeled oligonucleotide probe as described herein. In an embodiment, the ECL-labeled oligonucleotide probe comprises an oligonucleotide sequence complementary to the oligonucleotide sequence of the binding partner and / or binding complex oligonucleotide. In an embodiment, the binding partner and / or binding complex is immobilized on a substrate before being exposed to the ECL-labeled oligonucleotide probe, and in other embodiments, the binding partner and / or binding complex is immobilized on a substrate after being exposed to the ECL-labeled oligonucleotide probe. In an embodiment, the ECL-labeled probe comprises a quenching portion that quenches the ECL signal at least when the probe is not hybridized with a complementary oligonucleotide. In an embodiment, the ECL-labeled oligonucleotide probe comprises a stem-loop or hairpin structure, an ECL label and a quenching portion, wherein the quenching portion is close to the ECL label and quenches the ECL label when the oligonucleotide probe is in a stem-loop or hairpin configuration, but does not quench the ECL label when the stem-loop or hairpin structure is in an open configuration. In an embodiment, when the probe is in a linear configuration (e.g., not in a stem-loop or hairpin configuration), the ECL-labeled ECL label and the quencher are close enough to each other on the probe so that the quenching moiety quenches the ECL signal regardless of whether the probe is hybridized to a complementary oligonucleotide. In an embodiment, the ECL-labeled oligonucleotide probe is present in a composition containing a binding partner and / or a binding complex of a binding reagent, such that binding of the binding partner and / or the binding complex to the binding reagent immobilized on the substrate and exposure of the binding partner relative to the ECL-labeled oligonucleotide probe occur simultaneously. In an embodiment, the ECL-labeled oligonucleotide probe and the binding partner and / or binding complex comprising the oligonucleotide are first mixed together, and then the composition comprising the two is exposed to a substrate comprising an immobilized binding reagent. In an embodiment, the ECL-labeled oligonucleotide probe is added after the binding partner and / or binding complex is bound to the substrate via the binding reagent, if washing is performed, after the optional washing.
[0308] The ECL-labeled oligonucleotide probe is allowed to hybridize with the complementary oligonucleotide of the bound binding partner or binding complex. In embodiments where the ECL-labeled oligonucleotide probe has a stem-loop or hairpin structure with an ECL label and a quenching moiety, hybridization opens the stem-loop or hairpin structure, separating the ECL label from the quenching moiety so that the quenching moiety will no longer quench the ECL signal emitted by the ECL label. The conditions for hybridization of the ECL-labeled oligonucleotide probe with the complementary oligonucleotide on the binding partner can be conventional oligonucleotide probes known in the art (e.g., molecular beacon probes or hydrolysis probes (also known as probe)) conditions.
[0309] In an embodiment, the hybridized ECL-labeled oligonucleotide probe is selectively dequenched, cau...
Claims
1. An electrochemiluminescence (ECL) detection method, comprising: a) providing a substrate comprising an electrode and having a binding agent immobilized on a surface of the substrate; b) contacting the substrate with a composition comprising: i) a binding partner and / or a binding complex, said binding partner and / or binding complex comprising an oligonucleotide, wherein said binding agent binds to said binding partner and / or binding complex; ii) a plurality of ECL-labeled oligonucleotide probes comprising oligonucleotide sequences complementary to the oligonucleotide sequences of the oligonucleotides of the binding partner and / or the binding complex; and iii) an ECL co-reactant, wherein the ECL co-reactant is not TPA; c) allowing a portion of the plurality of ECL-labeled oligonucleotide probes to hybridize with the oligonucleotide of the binding partner and / or binding complex, wherein the binding partner and / or binding complex is bound by the binding reagent, and wherein another portion of the plurality of ECL-labeled oligonucleotide probes does not hybridize with the oligonucleotide of the binding partner and / or binding complex bound by the binding reagent; d) selectively dequenching the portion of the plurality of ECL-labeled probes hybridized to the binding partner and / or the oligonucleotide bound complex; e) applying a voltage to the electrodes to generate ECL; and f) measuring said ECL, wherein said portion of said plurality of ECL-labeled oligonucleotide probes that are not hybridized to said binding partner and / or said oligonucleotide of said binding complex is not removed from said composition prior to applying said voltage and measuring said ECL.
2. The method of claim 1, wherein b) contacting the substrate with the composition comprises: b') contacting the substrate with a composition comprising the binding partner and / or binding complex; b″) contacting the substrate with a composition comprising the plurality of ECL-labeled oligonucleotide probes; as well as b'") contacting the substrate with a composition comprising the ECL co-reactant.
3. The method according to claim 2, wherein each of steps b'), b") and b'") is performed sequentially.
4. The method according to claim 2, wherein at least two of steps b'), b") and b'") are performed simultaneously.
5. The method according to claim 1, wherein the method comprises: b') contacting the substrate with a first composition comprising the binding partner and / or binding complex, and allowing the binding partner and / or binding complex to be immobilized on the surface by binding to the binding agent; as well as b″) contacting the substrate comprising the immobilized binding partner and / or binding complex with a second composition comprising the plurality of ECL-labeled oligonucleotide probes and the ECL co-reactant; or b') contacting the substrate with a first composition comprising the binding partner and / or binding complex and the plurality of ECL-labeled oligonucleotide probes, wherein a portion of the plurality of ECL-labeled oligonucleotide probes hybridizes with the oligonucleotides of the binding partner and / or binding complex, and allowing the binding partner and / or binding complex to be immobilized on the surface by binding to the binding reagent; as well as b″) contacting the substrate comprising the immobilized binding partner and / or binding complex with a second composition comprising the ECL co-reactant; or b') contacting the substrate with a first composition comprising the binding partner and / or binding complex, and allowing the binding partner and / or binding complex to be immobilized on the surface by binding to the binding agent; as well as b″) contacting the substrate including the immobilized binding partner and / or binding complex with a second composition including the plurality of ECL-labeled oligonucleotide probes, and allowing a portion of the plurality of ECL-labeled oligonucleotide probes to hybridize with the oligonucleotides of the immobilized binding partner and / or binding complex; as well as b'") contacting the substrate with a third composition comprising the ECL co-reactant.
6. The method according to any one of claims 1 to 5, further comprising washing the substrate after contacting the substrate with the binding partner and / or binding complex to remove the binding partner and / or binding complex not bound by the binding reagent, wherein the washing is performed before contacting the substrate with the composition comprising the plurality of ECL-labeled oligonucleotide probes.
7. An electrochemiluminescence (ECL) detection method, comprising: a) providing a substrate comprising an electrode and having a binding partner and / or a binding complex comprising an oligonucleotide immobilized on the surface of the substrate; b) contacting the substrate with a composition comprising: i) a plurality of ECL-labeled oligonucleotide probes, said plurality of ECL-labeled oligonucleotide probes comprising an oligonucleotide sequence complementary to an oligonucleotide sequence of said binding partner and / or said oligonucleotide of said binding complex; and ii) an ECL co-reactant, wherein the ECL co-reactant is not TPA; c) allowing a portion of the plurality of ECL-labeled oligonucleotide probes to hybridize with the immobilized binding partner and / or the oligonucleotide of the binding complex, and wherein another portion of the plurality of ECL-labeled oligonucleotide probes does not hybridize with the immobilized binding partner and / or the oligonucleotide of the binding complex; d) selectively dequenching the portion of the plurality of ECL-labeled probes hybridized to the binding partner and / or the oligonucleotide bound complex; e) applying a voltage to the electrodes to generate ECL; and f) measuring said ECL, wherein said portion of said plurality of ECL-labeled oligonucleotide probes that are not hybridized to said binding partner and / or said oligonucleotide of said binding complex is not removed from said composition prior to applying said voltage and measuring said ECL.
8. The method of claim 7, wherein b) contacting the substrate with the composition comprises: b') contacting the substrate with a composition comprising the plurality of ECL-labeled oligonucleotide probes; as well as b") contacting the substrate with a composition comprising the ECL co-reactant.
9. The method according to claim 8, wherein each of steps b') and b") is performed sequentially.
10. The method of claim 8, wherein each of steps b') and b") is performed simultaneously, optionally wherein the plurality of ECL-labeled oligonucleotide probes and the ECL co-reactant are in a single composition.
11. The method according to any one of claims 1 to 10, wherein the binding partner and / or binding complex comprises an analyte.
12. The method of claim 11, wherein the analyte comprises a peptide.
13. The method of claim 11, wherein the analyte comprises an oligonucleotide.
14. The method according to claim 13, wherein the analyte is the binding partner and / or the oligonucleotide bound to the complex.
15. The method according to any one of claims 11 to 13, wherein the analyte is labeled with the oligonucleotide.
16. The method of claim 15, wherein the analyte is labeled with the oligonucleotide by binding the analyte to a detection reagent comprising the oligonucleotide.
17. The method according to any one of claims 1 to 16, wherein the oligonucleotide of the binding partner and / or binding complex comprises multiple copies of the sequence complementary to the oligonucleotide sequence of the plurality of ECL-labeled oligonucleotide probes.
18. The method of claim 17, further comprising, before contacting the substrate with the plurality of ECL-labeled oligonucleotide probes, performing an amplification reaction to generate the plurality of copies of the sequence complementary to the oligonucleotide sequence of the plurality of ECL-labeled oligonucleotide probes.
19. A method according to claim 16, wherein the analyte is labeled with the oligonucleotide by combining the analyte with a detection reagent comprising an oligonucleotide primer, and wherein the oligonucleotide primer is extended by a polymerase to produce oligonucleotides comprising the multiple copies of the sequence complementary to the oligonucleotide sequence of the ECL-labeled oligonucleotide probe.
20. The method according to claim 18 or 19, wherein the amplification reaction or primer extension is a rolling circle amplification reaction.
21. The method according to any one of claims 1 to 20, wherein the ECL-labeled oligonucleotide probe comprises a stem-loop or hairpin structure, an ECL label and a quenching moiety, wherein the quenching moiety is close to the ECL label and quenches the ECL label when the oligonucleotide probe is in a stem-loop or hairpin configuration, but does not quench the ECL label when the stem-loop or hairpin structure is in an open configuration, and wherein said selectively dequenching comprises hybridizing said portion of said plurality of ECL-labeled oligonucleotide probes to said oligonucleotide of said binding partner and / or binding complex in said open configuration.
22. The method according to any one of claims 1 to 20, wherein the ECL-labeled oligonucleotide probe comprises an ECL label and a quenching portion, wherein the quenching portion is adjacent to the ECL label and quenches the ECL label when the oligonucleotide probe is linearly confirmed, Wherein the selective dequenching comprises selectively cleaving the quenching portion from only the portion of the multiple ECL-labeled probes hybridized to the oligonucleotide of the binding partner and / or the binding complex, so that the quenching portion is released into the solution and is no longer close to the ECL label of the hybridized ECL-labeled probe, and after cleavage of the quenching portion, the hybridized ECL-labeled probe remains hybridized to the oligonucleotide of the binding partner and / or the binding complex.
23. The method of claim 22, wherein the cleavage is performed enzymatically.
24. The method of claim 23, wherein the enzyme is selected from the group consisting of: a nicking restriction endonuclease, RNase H2, and a polymerase with 5' exonuclease activity.
25. The method according to claim 23 or 24, wherein the enzyme only cleaves the ECL-labeled oligonucleotide probe, thereby leaving the binding partner and / or the oligonucleotide binding complex intact.
26. The method of claim 25, wherein the enzyme is a nicking restriction endonuclease that recognizes a sequence in the hybridized ECL-labeled probe, or RNase H2 that recognizes an RNA base in the hybridized ECL-labeled probe.
27. The method of claim 23, wherein the enzyme is a polymerase having 5' exonuclease activity, and wherein the method further comprises: hybridizing a primer to said binding partner and / or said oligonucleotide of the binding complex at a position 5' of said hybridized ECL-labeled probe, allowing the polymerase having 5' exonuclease activity to extend the primer to the hybridized ECL-labeled probe, wherein the 5' exonuclease activity cleaves the quenching portion of the hybridized ECL-labeled probe, and The ECL-labeled probe comprises a portion resistant to the 5' exonuclease activity.
28. The method of any one of claims 1 to 27, wherein the ECL coreactant is selected from the group consisting of: 3-(di-n-propylamino)-propanesulfonic acid; 4-(di-n-propylamino)-butanesulfonic acid; 4-[bis-(2-hydroxyethane)-amino]-butanesulfonic acid; piperidine-N-(3-propanesulfonic acid); azepane-N-(3-propanesulfonic acid); piperidine-N-(3-propionic acid) (PPA); 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO); 3-morpholinopropanesulfonic acid (MOP S); N-(2-hydroxyethyl)piperazine-N'-3-propanesulfonic acid (EPPS); N-(2-hydroxyethyl)piperazine-N'-3-ethanesulfonic acid (BES); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); triethanolamine (TEA); N-2-hydroxypiperazine-N-2-ethanesulfonic acid (HEPES); piperazine-N,N'-bis-4-butanesulfonic acid; homopiperidinyl-N-3-propanesulfonic acid; piperazine-N,N'-bis-3-propanesulfonic acid; piperidine-N-3-propanesulfonic acid; piperazine-N-2 -Hydroxyethane-N'-3-methylpropionate; piperazine-N,N'-bis-3-methylpropionate; 1,6-diaminohexane-N,N,N',N'-tetraacetic acid; N,N-dipropyl-N-4-aminobutanesulfonic acid; N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); 1,3-bis[tris(hydroxymethyl)methylamino]propane (bis-tripropane); 3-dimethylamino-1-propanol; 3-dimethylamino-2-propanol; N,N,N',N'-tetrapropylpropane-1,3- diamine (TPA dimer); piperazine-N,N'-bis(2-hydroxypropane)sulfonic acid (POPSO) and 2-hydroxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid (HEPPSO), n-butyldiethanolamine (BDEA), 2-dibutylaminoethanol (DBAE), tert-butyldiethanolamine (tBDEA), methyldiethanolamine (MDEA), 3-[bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS) and combinations thereof.
29. The method of any one of claims 1 to 27, wherein the ECL co-reactant is TEA, or is selected from the group consisting of TEA, BDEA, MDEA, DEA-PS, and combinations thereof.
30. The method of any one of claims 1 to 29, wherein the quenching moiety is selected from the group consisting of ATTO 540Q, ATTO 575Q, ATTO 580Q, ATTO 612Q, Iowa Black FQ, Iowa BackRQ, QSY 21, IRDye QC-1, BHQ0, BHQ1, BHQ-2, BHQ-3, Dabcyl, QSY 7, QSY 9, QSY 21, QSY 35, QXL 490, QXL520, QXL 570, QXL 670, ferrocene, ferrobipyridine, and combinations thereof.
31. The method of any one of claims 1 to 30, wherein the ECL label is an organometallic complex comprising ruthenium, osmium, iridium, rhenium and / or a lanthanide metal.
32. The method of any one of claims 1 to 31, wherein the ECL label comprises tris(bipyridine)ruthenium or modified tris(bipyridine)ruthenium.
33. The method of claim 32, wherein the ECL label comprises the chemical structure shown in Formula II:
34. The method of any one of claims 1 to 33, wherein the co-reactant is in the composition of any one of numbered items 1 to 69.
Citation Information
Patent Citations
Assay methods
US10114015B2
Assay methods
US10408823B2
Assay Cartridges and Methods of Using the Same
US20120178091A1
Assay Cartridges and Methods of Using the Same
US20120190589A1
Assay methods
US20170168047A1
